Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Hepatol
    November 2025
  1. TORP N, Israelsen M, Thiele M, Rinella ME, et al
    Phosphatidylethanol in steatotic liver disease.
    J Hepatol. 2025;83:1189-1203.
    >> Share

  2. JAECKEL E, Friedman SL, Hudecek M, Protzer U, et al
    Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases.
    J Hepatol. 2025;83:1156-1171.
    >> Share

  3. TAVAGLIONE F, Diaz LA, Ajmera V, Madamba E, et al
    Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification.
    J Hepatol. 2025;83:1023-1034.
    >> Share

  4. ALGUERO-NADAL A, Mol H, Zoppolato E, Kowalczyk W, et al
    Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation.
    J Hepatol. 2025;83:1142-1155.
    >> Share

  5. LIU J, Xiao S, Hu S, Huang R, et al
    Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles.
    J Hepatol. 2025;83:1035-1045.
    >> Share

  6. VAZ J, Nasr P, Helander A, Shang Y, et al
    Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes.
    J Hepatol. 2025;83:1011-1022.
    >> Share

    October 2025
  7. CUI T, Sun L, Guo X, Cheng C, et al
    Corrigendum to 'Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response' (J Hepatol 2025 [946-958]).
    J Hepatol. 2025 Oct 27:S0168-8278(25)02554-1. doi: 10.1016/j.jhep.2025.
    >> Share

  8. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
    Corrigendum to: "Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study" [J Hepatol (2024) 278-288].
    J Hepatol. 2025 Oct 27:S0168-8278(25)02553-X. doi: 10.1016/j.jhep.2025.
    >> Share

  9. BANARES J, Pons M, Reiberger T, Mandorfer M, et al
    Refining the Baveno VII criteria for clinically significant portal hypertension: an individual-patient data meta-analysis.
    J Hepatol. 2025 Oct 23:S0168-8278(25)02565-6. doi: 10.1016/j.jhep.2025.
    >> Share

  10. GLYNN AM, Faye MD, Gerard IJ, Vanner RJ, et al
    Stereotactic body radiotherapy treatment for hepatocellular carcinoma with extensive macrovascular invasion.
    J Hepatol. 2025 Oct 17:S0168-8278(25)02559-0. doi: 10.1016/j.jhep.2025.
    >> Share

  11. CELSA C, Pinato DJ, Cabibbo G
    "Advancing Clinical Trial Design and Patient Care in Hepatocellular Carcinoma".
    J Hepatol. 2025 Oct 17:S0168-8278(25)02558-9. doi: 10.1016/j.jhep.2025.
    >> Share

  12. YUAN H, Zhao L, Yang G, Zhang S, et al
    HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses.
    J Hepatol. 2025 Oct 16:S0168-8278(25)02556-5. doi: 10.1016/j.jhep.2025.
    >> Share

  13. QIAN S, He Y
    Alcohol consumption potentiates second-hit events in HBV-induced hepatocellular carcinoma.
    J Hepatol. 2025 Oct 10:S0168-8278(25)02548-6. doi: 10.1016/j.jhep.2025.
    >> Share

  14. TELLEZ L, Donate J, Guerrero A, Beraza IA, et al
    Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort.
    J Hepatol. 2025 Oct 9:S0168-8278(25)02490-0. doi: 10.1016/j.jhep.2025.
    >> Share

  15. WEDEMEYER H, Tacke F, Newsome P, Ratziu V, et al
    The first human xenogeneic liver transplantation - A landmark event, but what does it mean for hepatology?
    J Hepatol. 2025 Oct 9:S0168-8278(25)02496-1. doi: 10.1016/j.jhep.2025.
    >> Share

  16. THEVENOT T, Desmarets M, Tio G
    Primary prophylaxis of spontaneous bacterial peritonitis using rifaximin in patients with severe cirrhosis and ascites, not the end of the story?
    J Hepatol. 2025 Oct 9:S0168-8278(25)02551-6. doi: 10.1016/j.jhep.2025.
    >> Share

  17. GARG P, Verma N, Jalan R
    Reply to: RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
    J Hepatol. 2025 Oct 9:S0168-8278(25)02549-8. doi: 10.1016/j.jhep.2025.
    >> Share

  18. CHEN F, Tchorz JS
    Postnatal hepatocyte proliferation - challenge and opportunity for gene therapy.
    J Hepatol. 2025 Oct 6:S0168-8278(25)02520-6. doi: 10.1016/j.jhep.2025.
    >> Share

  19. RUDLER M
    Preemptive TIPS in patients with cirrhosis and acute variceal bleeding related to gastric varices: The GAVAPROSEC trial.
    J Hepatol. 2025 Oct 6:S0168-8278(25)02476-6. doi: 10.1016/j.jhep.2025.
    >> Share

  20. OCHOA-ALLEMANT P, Hubbard RA, Kaplan DE, Serper M, et al
    Cause-specific mortality in patients with steatotic liver disease in the United States.
    J Hepatol. 2025;83:860-869.
    >> Share

  21. DIAZ LA, Alazawi W, Agrawal S, Arab JP, et al
    High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.
    J Hepatol. 2025;83:849-859.
    >> Share

  22. RIMASSA L, Chan SL, Sangro B, Lau G, et al
    Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
    J Hepatol. 2025;83:899-908.
    >> Share

  23. ZHANG XF, Zuo XY, Zhu Y, Li JX, et al
    Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma.
    J Hepatol. 2025 Oct 1:S0168-8278(25)02517-6. doi: 10.1016/j.jhep.2025.
    >> Share

    September 2025
  24. GALANAKIS V, Gribben C, Munteanu A, Cagna M, et al
    Transcriptomic and epigenetic mechanisms controlling cholangiocytes transdifferentiation into hepatocytes.
    J Hepatol. 2025 Sep 29:S0168-8278(25)02516-4. doi: 10.1016/j.jhep.2025.
    >> Share

  25. LISMAN T, Puente A, Garcia-Pagan JC
    Anticoagulant therapy to delay disease progression in patients with cirrhosis - reponse to Acka et al., Bot et al. and Feng et al.
    J Hepatol. 2025 Sep 25:S0168-8278(25)02495-X. doi: 10.1016/j.jhep.2025.
    >> Share

  26. VERMA N, Kaur P, Garg P, Ranjan V, et al
    Corrigendum to "Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis" [J Hepatol (2025) https://doi.org/10.1016/j.jhep.2025.02.028].
    J Hepatol. 2025 Sep 25:S0168-8278(25)02475-4. doi: 10.1016/j.jhep.2025.
    >> Share

  27. ZHANG T
    RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
    J Hepatol. 2025 Sep 24:S0168-8278(25)02499-7. doi: 10.1016/j.jhep.2025.
    >> Share

  28. HSU C
    Engineered T cell therapy for hepatocellular carcinoma: the dawn of precision immunotherapy?
    J Hepatol. 2025 Sep 23:S0168-8278(25)02491-2. doi: 10.1016/j.jhep.2025.
    >> Share

  29. MAURO E, de Castro T, Zeitlhoefler M, Hackshaw A, et al
    Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma.
    J Hepatol. 2025 Sep 22:S0168-8278(25)02492-4. doi: 10.1016/j.jhep.2025.
    >> Share

  30. LIN YJ, Ou DL, Su YY, Hsu CL, et al
    Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration.
    J Hepatol. 2025 Sep 17:S0168-8278(25)02471-7. doi: 10.1016/j.jhep.2025.
    >> Share

  31. AKCA M, Ketenci YB, Demiroz H, Avcioglu U, et al
    Concerns on Rivaroxaban Use in Cirrhosis: Pharmacokinetic, Safety, and Bleeding Risk Considerations.
    J Hepatol. 2025 Sep 17:S0168-8278(25)02489-4. doi: 10.1016/j.jhep.2025.
    >> Share

  32. PINATO DJ
    Immunotherapy in advanced hepatocellular cancer: The last piece of the puzzle.
    J Hepatol. 2025 Sep 5:S0168-8278(25)02384-0. doi: 10.1016/j.jhep.2025.
    >> Share

  33. FORTEA JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, et al
    Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80].
    J Hepatol. 2025 Sep 5:S0168-8278(25)02439-0. doi: 10.1016/j.jhep.2025.
    >> Share

  34. KIM HD, Sym SJ, Chon HJ, Kim M, et al
    Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
    J Hepatol. 2025 Sep 4:S0168-8278(25)02457-2. doi: 10.1016/j.jhep.2025.
    >> Share

  35. ALLAIRE M, Meneghetti AR, Mouri S, Kather JN, et al
    A Role of Non-Selective Beta-Blockers in Preventing Liver Decompensation in Patients with Hepatocellular Carcinoma Undergoing Systemic Therapy.
    J Hepatol. 2025 Sep 3:S0168-8278(25)02469-9. doi: 10.1016/j.jhep.2025.
    >> Share

  36. ZHOU T
    Optimizing Clinical Adoption of Large Language Models in Hepatology: Toward Terminological Precision, Multilingual Adaptability, and Interpretive Literacy.
    J Hepatol. 2025 Sep 2:S0168-8278(25)02470-5. doi: 10.1016/j.jhep.2025.
    >> Share

  37. NEUSCHWANDER-TETRI BA, Akbary K, Carpenter DH, Noureddin M, et al
    The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials.
    J Hepatol. 2025;83:790-799.
    >> Share

  38. ISSA G, Shang Y, Strandberg R, Hagstrom H, et al
    Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden.
    J Hepatol. 2025;83:643-651.
    >> Share

    August 2025
  39. DIXON ED, Claudel T, Nardo AD, Riva A, et al
    Erratum to 'Inhibition of ATGL alleviates MASH via impaired PPARa signalling that favours hydrophilic bile acid composition in mice' [J Hepatol 82 (2025) 658-675].
    J Hepatol. 2025 Aug 30:S0168-8278(25)02438-9. doi: 10.1016/j.jhep.2025.
    >> Share

  40. ZHOU H, Ba J, Xiao C, Liu H, et al
    Alcohol activates ATF4/LPLA2-mediated BMP metabolism to enhance HBV-induced hepatocellular carcinogenesis.
    J Hepatol. 2025 Aug 28:S0168-8278(25)02458-4. doi: 10.1016/j.jhep.2025.
    >> Share

  41. CHAN SL, Lamarca A, Hsu C, Moreno V, et al
    New targets and new drugs for hepatobiliary cancers.
    J Hepatol. 2025 Aug 25:S0168-8278(25)02455-9. doi: 10.1016/j.jhep.2025.
    >> Share

  42. VERMA N, Kaur P, Jalan R
    Disease Staging and Clinical State in Cirrhosis: Is severity, acuity and pathophysiology the missing link?
    J Hepatol. 2025 Aug 25:S0168-8278(25)02456-0. doi: 10.1016/j.jhep.2025.
    >> Share

  43. ROMERO-CRISTOBAL M
    Cirrhosis recompensation: what it is and what it ought to be - insights from the philosophy of science.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02449-3. doi: 10.1016/j.jhep.2025.
    >> Share

  44. RIDOLA L, Riggio O
    Rifaximin and Survival in Cirrhosis: An Unmet Clinical Promise.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02446-8. doi: 10.1016/j.jhep.2025.
    >> Share

  45. TRAMPERT DC
    From parts to portal: Recapitulating hepatobiliary microarchitecture using multicellular organoids.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02346-3. doi: 10.1016/j.jhep.2025.
    >> Share

  46. VERMA N, Garg P, Kaur P, Munjal S, et al
    Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosis.
    J Hepatol. 2025 Aug 12:S0168-8278(25)02405-5. doi: 10.1016/j.jhep.2025.
    >> Share

  47. MEYER T, Finn RS, Borad M, Mahipal A, et al
    Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
    J Hepatol. 2025 Aug 12:S0168-8278(25)02404-3. doi: 10.1016/j.jhep.2025.
    >> Share

  48. BOT KK, Ezzafzafi S, Lantinga MA
    Not all DOACs are created equal, revisiting the safety of rivaroxaban for the prevention of portal hypertension-related complications.
    J Hepatol. 2025 Aug 5:S0168-8278(25)02396-7. doi: 10.1016/j.jhep.2025.
    >> Share

  49. BREVINI T, Swift L, Reynolds H, Ong J, et al
    Successful AAV8 gene therapy on hepatic ex situ machine perfusion for mitochondrial neurogastrointestinal encephalomyopathy.
    J Hepatol. 2025 Aug 5:S0168-8278(25)02388-8. doi: 10.1016/j.jhep.2025.
    >> Share

  50. ZHANG R, Su L, Fu M, Wang Z, et al
    Corrigendum to: 'CD177(+) cells produce neutrophil extracellular traps that promote biliary atresia' (J Hepatol [2022] 77:1299-1310).
    J Hepatol. 2025 Aug 4:S0168-8278(25)02281-0. doi: 10.1016/j.jhep.2025.
    >> Share

  51. CABIBBO G, Celsa C, Bhoori S, Reiberger T, et al
    Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02386-4. doi: 10.1016/j.jhep.2025.
    >> Share

  52. PIANO S, Patidar KR, Juanola A
    Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: enough, but not too much.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02395-5. doi: 10.1016/j.jhep.2025.
    >> Share

  53. HE J, Zhang M, Shi Y, Ji Z, et al
    Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02382-7. doi: 10.1016/j.jhep.2025.
    >> Share

  54. NADIM MK, Kellum JA, Durand F
    From Protocol to Precision: The Evolving Diagnosis of Hepatorenal Syndrome.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02393-1. doi: 10.1016/j.jhep.2025.
    >> Share

  55. BJORN AB, Jensen MD, Pero A, Villadsen GE, et al
    Male-to-female ratios in the risk of hepatocellular carcinoma: A nationwide study of Danish patients with viral or non-viral cirrhosis.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02390-6. doi: 10.1016/j.jhep.2025.
    >> Share

  56. STEINBERG GR, Valvano CM, De Nardo W, Watt MJ, et al
    Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms.
    J Hepatol. 2025;83:584-595.
    >> Share

  57. HARRISON SA, Alkhouri N, Ortiz-Lasanta G, Rudraraju M, et al
    A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.
    J Hepatol. 2025;83:293-303.
    >> Share

  58. STURM L, Schultheiss M, Stohr F, Labenz C, et al
    Freiburg index of post-TIPS survival (FIPS) identifies patients at risk of further decompensation and ACLF after TIPS.
    J Hepatol. 2025;83:348-357.
    >> Share

  59. YIP TC, Lee HW, Lin H, Tsochatzis E, et al
    Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2025;83:304-314.
    >> Share

  60. DING W, Meng Y, Ma J, Pang C, et al
    Contrast-enhanced ultrasound-based AI model for multi-classification of focal liver lesions.
    J Hepatol. 2025;83:426-439.
    >> Share

  61. VERMA N, Angeli P, Jalan R
    Stratification, Therapeutic Targeting and Towards Personalised Care in Cirrhosis.
    J Hepatol. 2025 Aug 1:S0168-8278(25)02378-5. doi: 10.1016/j.jhep.2025.
    >> Share

    July 2025
  62. RUDLER M
    Simvastatin and rifaximin in patients with decompensated cirrhosis: Still a place for LIVER HOPE?
    J Hepatol. 2025 Jul 30:S0168-8278(25)02323-2. doi: 10.1016/j.jhep.2025.
    >> Share

  63. PUENTE A, Turon F, Martinez J, Fortea JI, et al
    Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study.
    J Hepatol. 2025 Jul 19:S0168-8278(25)02336-0. doi: 10.1016/j.jhep.2025.
    >> Share

  64. LIU H, Wang J, Yao Y, Xia T, et al
    Restoration of N-glycosylation via leucine-activated leucyl-tRNA synthetase 1 overcomes chemoresistance in intrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02344-X. doi: 10.1016/j.jhep.2025.
    >> Share

  65. PU X, Liu Y, Lyu Z, Zhou Y, et al
    B cells drive CCR5(+)CD4(+) tissue-resident memory T cell cytotoxicity via IL-15Ralpha-IL-15 signaling in primary biliary cholangitis.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02340-2. doi: 10.1016/j.jhep.2025.
    >> Share

  66. CLUSMANN J, Balaguer-Montero M, Bassegoda O, Schneider CV, et al
    The barriers for uptake of artificial intelligence in hepatology and how to overcome them.
    J Hepatol. 2025 Jul 16:S0168-8278(25)02337-2. doi: 10.1016/j.jhep.2025.
    >> Share

  67. VITHAYATHIL M, Koku D, Aboagye EO, Sharma R, et al
    Reply to: "Reevaluating Feature Selection in Machine Learning-Based Radiomics for Hepatocellular Carcinoma: Bridging the Gap Between Predictive Accuracy and Biological Relevance".
    J Hepatol. 2025 Jul 12:S0168-8278(25)02341-4. doi: 10.1016/j.jhep.2025.
    >> Share

  68. THEVENOT T, Elkrief L, Bureau C, Bardou-Jacquet E, et al
    Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled clinical trial.
    J Hepatol. 2025 Jul 11:S0168-8278(25)02318-9. doi: 10.1016/j.jhep.2025.
    >> Share

  69. KWOK GW, Wing Fung TH, Yau T
    Fulminant Tumour Lysis Syndrome after Nivolumab and Ipilimumab treatment for Hepatocellular Carcinoma.
    J Hepatol. 2025 Jul 9:S0168-8278(25)02331-1. doi: 10.1016/j.jhep.2025.
    >> Share

  70. GUAN X, Yang Y, Li Y, Shao C, et al
    Hepatic encephalopathy in a 16-year-old girl: A case of adult-onset hereditary metabolic liver disease.
    J Hepatol. 2025 Jul 9:S0168-8278(25)02328-1. doi: 10.1016/j.jhep.2025.
    >> Share

  71. RAMACHANDRAN P
    Hepatic stellate cells regulate multiple aspects of hepatocyte function in health and disease.
    J Hepatol. 2025 Jul 7:S0168-8278(25)02248-2. doi: 10.1016/j.jhep.2025.
    >> Share

  72. ZENG Q, Patel S, Wang X, Hsieh MH, et al
    Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation.
    J Hepatol. 2025 Jul 4:S0168-8278(25)02320-7. doi: 10.1016/j.jhep.2025.
    >> Share

  73. MILANI M, Starinieri F, Beretta S, Monti M, et al
    Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering.
    J Hepatol. 2025 Jul 3:S0168-8278(25)02317-7. doi: 10.1016/j.jhep.2025.
    >> Share


  74. EASL Clinical Practice Guidelines on TIPS.
    J Hepatol. 2025;83:177-210.
    >> Share

  75. DE ZAWADZKI A, Leeming DJ, Sanyal AJ, Anstee QM, et al
    Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.
    J Hepatol. 2025;83:239-257.
    >> Share

  76. POSE E, Piano S, Thiele M, Fabrellas N, et al
    Moving diagnosis of liver fibrosis into the community.
    J Hepatol. 2025;83:258-270.
    >> Share

  77. WALLACE C, Gamkrelidze I, Estes C, Razavi H, et al
    Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States.
    J Hepatol. 2025;83:21-30.
    >> Share

  78. SUN Y, Xu M, Wan HL, Ding X, et al
    Spliced exon9 ADRM1 promotes liver oncogenicity via selective degradation of tumor suppressor FBXW7.
    J Hepatol. 2025;83:92-104.
    >> Share

  79. DONG R, Wang T, Dong W, Zhang H, et al
    TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway.
    J Hepatol. 2025;83:105-118.
    >> Share

  80. GONCALVES T, Letrillart L, Carlier C, Boulagnon-Rombi C, et al
    Dysphagia associated with portal hypertension and hepatocellular carcinoma, singular coincidence or hidden pathway?
    J Hepatol. 2025;83:e13-e15.
    >> Share

  81. ALLEN AM, Kamath PS
    Staging decompensated cirrhosis: Lumping, splitting, or just rearranging the deck chairs on the Titanic?
    J Hepatol. 2025 Jul 1:S0168-8278(25)02198-1. doi: 10.1016/j.jhep.2025.
    >> Share

    June 2025
  82. SANYAL AJ, Taubel J, Badri P, Bond S, et al
    Phase 1 randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis.
    J Hepatol. 2025 Jun 26:S0168-8278(25)02270-6. doi: 10.1016/j.jhep.2025.
    >> Share

  83. BEUERS U, Banales JM, Karpen S, Keitel V, et al
    History and prospects of bile acid therapies.
    J Hepatol. 2025 Jun 20:S0168-8278(25)02277-9. doi: 10.1016/j.jhep.2025.
    >> Share

  84. RODRIGUEZ N, Katzenstein C, O'Kula S, Kushner T, et al
    Use of maralixibat in severe and recurrent intrahepatic cholestasis of pregnancy with concurrent benign recurrent intrahepatic cholestasis (BRIC).
    J Hepatol. 2025 Jun 18:S0168-8278(25)02249-4. doi: 10.1016/j.jhep.2025.
    >> Share

  85. CHEUK-FUNG YIP T, Wai-Sun Wong V
    Reply to: "Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease" and "Risk stratification beyond fibrosis in SLD: The case for lifestyle-responsive prognostic to
    J Hepatol. 2025 Jun 6:S0168-8278(25)02265-2. doi: 10.1016/j.jhep.2025.
    >> Share

  86. TRAMPERT DC
    Bile acid species as hepatic T lymphocyte response modulators - when bile acids interfere with tumor growth.
    J Hepatol. 2025 Jun 5:S0168-8278(25)00249-1. doi: 10.1016/j.jhep.2025.
    >> Share

  87. CINNAMON E, Stein I, Zino E, Rabinovich S, et al
    RORc-expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions.
    J Hepatol. 2025;82:1050-1067.
    >> Share

  88. XIANG L, Wang G, Zhuang Y, Luo L, et al
    Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.
    J Hepatol. 2025;82:967-978.
    >> Share

  89. INDIA-ALDANA S, Midya V, Betanzos-Robledo L, Yao M, et al
    Impact of metabolism-disrupting chemicals and folic acid supplementation on liver injury and steatosis in mother-child pairs.
    J Hepatol. 2025;82:956-966.
    >> Share

  90. WANG Y, Wang J, Zhou Z, Gu Y, et al
    A read-through circular RNA RCRIN inhibits metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2025;82:1068-1079.
    >> Share

    May 2025
  91. TAKEFUJI Y
    Reevaluating Feature Selection in Machine Learning-Based Radiomics for Hepatocellular Carcinoma: Bridging the Gap Between Predictive Accuracy and Biological Relevance.
    J Hepatol. 2025 May 29:S0168-8278(25)02258-5. doi: 10.1016/j.jhep.2025.
    >> Share

  92. CHEW V
    Harnessing spatial immunity to predict recurrence in hepatocellular carcinoma.
    J Hepatol. 2025 May 27:S0168-8278(25)00239-9. doi: 10.1016/j.jhep.2025.
    >> Share

  93. ENGELMANN C
    Rethinking hepatic encephalopathy: Gut microbes, neurotoxins and the therapeutic horizon.
    J Hepatol. 2025 May 27:S0168-8278(25)00295-8. doi: 10.1016/j.jhep.2025.
    >> Share

  94. ZHANG X, Shen J, Man K, Chu ESH, et al
    Corrigendum to "CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis" [J Hepatol (2014) 61:1365-75].
    J Hepatol. 2025 May 24:S0168-8278(25)00157-6. doi: 10.1016/j.jhep.2025.
    >> Share

  95. RUDLER M
    Autologous macrophage therapy for compensated cirrhosis, some hope at the horizon.
    J Hepatol. 2025 May 23:S0168-8278(25)00248-X. doi: 10.1016/j.jhep.2025.
    >> Share

  96. ISBISTER G, Chiew A, Buckley N, Harris K, et al
    A non-inferiority randomised controlled trial of a Shorter Acetylcysteine Regimen for Paracetamol Overdose - the SARPO trial.
    J Hepatol. 2025 May 23:S0168-8278(25)02206-8. doi: 10.1016/j.jhep.2025.
    >> Share

  97. GHALLAB A, Mandorfer M, Stirnimann G, Geyer J, et al
    Enteronephrohepatic Circulation of Bile Acids and Therapeutic Potential of Systemic Bile Acid Transporter Inhibitors.
    J Hepatol. 2025 May 23:S0168-8278(25)02207-X. doi: 10.1016/j.jhep.2025.
    >> Share

  98. HIRSCH TZ
    Immune exclusion in hepatoblastoma: is beta-catenin to blame again?
    J Hepatol. 2025 May 21:S0168-8278(25)02203-2. doi: 10.1016/j.jhep.2025.
    >> Share


  99. EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease.
    J Hepatol. 2025 May 8:S0168-8278(25)00235-1. doi: 10.1016/j.jhep.2025.
    >> Share

  100. CHRISTAKI M, Biros D, Tsiakas I, Milionis H, et al
    Carvedilol is superior to propranolol in preventing first and further decompensation, and mortality in patients with cirrhosis.
    J Hepatol. 2025 May 7:S0168-8278(25)00291-0. doi: 10.1016/j.jhep.2025.
    >> Share

  101. CALES P, Canivet CM, Costentin C, Lannes A, et al
    A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD.
    J Hepatol. 2025;82:794-804.
    >> Share

  102. ABDURRACHIM D, Lek S, Ong CZL, Wong CK, et al
    Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.
    J Hepatol. 2025;82:898-908.
    >> Share

  103. TAN EY, Danpanichkul P, Yong JN, Yu Z, et al
    Liver cancer in 2021: Global Burden of Disease study.
    J Hepatol. 2025;82:851-860.
    >> Share

    April 2025
  104. AM FULGENZI C, Dalla Pria A, Leone AG, Celsa C, et al
    Hepatocellular carcinoma in people living with HIV.
    J Hepatol. 2025 Apr 30:S0168-8278(25)00287-9. doi: 10.1016/j.jhep.2025.
    >> Share

  105. RAN S, Zhang J, Tian F, Qian ZM, et al
    Corrigendum to "Association of metabolic signatures of air pollution with MASLD: Observational and Mendelian randomization study" [J Hepatol (2025) 10.1016/j.jhep.2024.09.033].
    J Hepatol. 2025 Apr 28:S0168-8278(25)00225-9. doi: 10.1016/j.jhep.2025.
    >> Share

  106. JEONG S
    Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease.
    J Hepatol. 2025 Apr 22:S0168-8278(25)00250-8. doi: 10.1016/j.jhep.2025.
    >> Share

  107. ANGELI P, Labenz C, Piano S, Juanola A, et al
    Albumin infusion in Hepatorenal Syndrome-Acute Kidney Injury: new evidence challenges recent consensus.
    J Hepatol. 2025 Apr 16:S0168-8278(25)00238-7. doi: 10.1016/j.jhep.2025.
    >> Share

  108. REIBERGER T, Maasoumy B
    Advancing our understanding of recompensated cirrhosis - the new "holy grail" of decompensated cirrhosis.
    J Hepatol. 2025 Apr 16:S0168-8278(25)00241-7. doi: 10.1016/j.jhep.2025.
    >> Share

  109. VITHAYATHIL M, Koku D, Campani C, Nault JC, et al
    Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma.
    J Hepatol. 2025 Apr 15:S0168-8278(25)00244-2. doi: 10.1016/j.jhep.2025.
    >> Share

  110. FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA
    Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025.
    >> Share

  111. TONON M, Gagliardi R, Pompili E, Barone A, et al
    Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00245-4. doi: 10.1016/j.jhep.2025.
    >> Share

  112. NAIK I, Yeo YH, Ng WH, Sheng-Kai Ma K, et al
    Carvedilol is Associated with Lower Risk of Hepatic Decompensation Compared to Other Non-Selective Beta-Blockers in Cirrhosis.
    J Hepatol. 2025 Apr 11:S0168-8278(25)00232-6. doi: 10.1016/j.jhep.2025.
    >> Share

  113. ALI K, Al Snih GM, Beyder A, Abdelmalek MF, et al
    Peppermint Oil Associated Hepatotoxicity.
    J Hepatol. 2025 Apr 9:S0168-8278(25)00230-2. doi: 10.1016/j.jhep.2025.
    >> Share

  114. SUN SS, Zhang J, Jin YP, Li L, et al
    A Rare Cause of Lipid Metabolism Disorder and Cirrhosis in an Adult.
    J Hepatol. 2025 Apr 9:S0168-8278(25)00227-2. doi: 10.1016/j.jhep.2025.
    >> Share

  115. ARAB JP, Diaz LA, Rehm J, Im G, et al
    Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease.
    J Hepatol. 2025;82:744-756.
    >> Share

  116. MEIJNIKMAN AS, Fondevila MF, Arrese M, Kisseleva T, et al
    Towards more consistent models and consensual terminology in preclinical research for steatotic liver disease.
    J Hepatol. 2025;82:760-766.
    >> Share

  117. VILAR-GOMEZ E, Gawrieh S, Vuppalanchi R, Kettler C, et al
    PNPLA3 rs738409, environmental factors and liver-related mortality in the US population.
    J Hepatol. 2025;82:571-581.
    >> Share

  118. BURKE L, Bernal W, Pirani T, Agarwal B, et al
    Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort.
    J Hepatol. 2025;82:615-621.
    >> Share

  119. YANG X, Deng B, Zhao W, Guo Y, et al
    FABP5(+) lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity.
    J Hepatol. 2025;82:676-689.
    >> Share

  120. RAN S, Zhang J, Tian F, Qian ZM, et al
    Association of metabolic signatures of air pollution with MASLD: Observational and Mendelian randomization study.
    J Hepatol. 2025;82:560-570.
    >> Share

    March 2025
  121. ZHOU S, Zhang L, You Y, Yu K, et al
    eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.
    J Hepatol. 2025 Mar 26:S0168-8278(25)00206-5. doi: 10.1016/j.jhep.2025.
    >> Share

  122. SHAWCROSS DL, Patel VC
    FMT for Hepatic Encephalopathy? The THEMATIC Trial aims to make is a 'no brainer'.
    J Hepatol. 2025 Mar 25:S0168-8278(25)00165-5. doi: 10.1016/j.jhep.2025.
    >> Share

  123. YU H, Ma Y
    Reply to: "An ER Transmembrane Protein Protects Against Hepatic Ischemia-Reperfusion Injury By Inhibiting ER-phagy and Apoptosis?".
    J Hepatol. 2025 Mar 21:S0168-8278(25)00170-9. doi: 10.1016/j.jhep.2025.
    >> Share

  124. SCHLEICHER EM, Karbannek H, Weinmann-Menke J, Galle PR, et al
    Effect of albumin treatment duration on response rates and outcomes in patients with cirrhosis and acute kidney injury.
    J Hepatol. 2025 Mar 19:S0168-8278(25)00164-3. doi: 10.1016/j.jhep.2025.
    >> Share

  125. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
    Erratum to: 'Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis' [J Hepatol (2024) 80:268-281].
    J Hepatol. 2025 Mar 15:S0168-8278(25)00140-0. doi: 10.1016/j.jhep.2025.
    >> Share

  126. LARSON EL, Ellias SD, Blezek DJ, Klug J, et al
    Simultaneous liver transplant and sleeve gastrectomy provides durable weight loss, improves metabolic syndrome and reduces allograft steatosis.
    J Hepatol. 2025 Mar 13:S0168-8278(25)00139-4. doi: 10.1016/j.jhep.2025.
    >> Share

  127. LANTINGA MA, Tapper EB, Drenth JPH
    Reply: Revisiting the use of albumin in patients with cirrhosis - trial design matters.
    J Hepatol. 2025 Mar 12:S0168-8278(25)00161-8. doi: 10.1016/j.jhep.2025.
    >> Share

  128. VERMA N, Kaur P, Garg P, Ranjan V, et al
    Clinical and Pathophysiological Characteristics of Non-acute Decompensation of Cirrhosis.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00137-0. doi: 10.1016/j.jhep.2025.
    >> Share

  129. SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al
    Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025.
    >> Share

  130. WANG H, Guo M, Ren B, Zhang H, et al
    Circadian Control of Hepatic Ischemia/Reperfusion Injury via HSD17B13-Mediated Autophagy in Hepatocytes.
    J Hepatol. 2025 Mar 4:S0168-8278(25)00138-2. doi: 10.1016/j.jhep.2025.
    >> Share

  131. ALKHOURI N, Beyer C, Shumbayawonda E, Andersson A, et al
    Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH.
    J Hepatol. 2025;82:438-445.
    >> Share

  132. TELLEZ L, Rincon D, Payance A, Jaillais A, et al
    Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort.
    J Hepatol. 2025;82:480-489.
    >> Share

  133. ZHONG Q, Zhou R, Huang YN, Huang RD, et al
    Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases.
    J Hepatol. 2025;82:427-437.
    >> Share


  134. Expression of concern to "Nitric oxide mimics transcriptional and post-translational regulation during alpha-Tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes" [J Hepatol. 2011 Jul;55(1):133-44].
    J Hepatol. 2025;82:548.
    >> Share

  135. CASTOLDI M, Roy S, Angendohr C, Pellegrino R, et al
    Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma.
    J Hepatol. 2025;82:499-511.
    >> Share

    February 2025
  136. NADIM MK, Kellum JA, Durand F
    Response to "Inclusion of patients with active urinary sediment in treatment of hepatorenal syndrome" by Hamadah A. and Gharaibeh K.
    J Hepatol. 2025 Feb 28:S0168-8278(25)00147-3. doi: 10.1016/j.jhep.2025.
    >> Share

  137. LAU G, Abou-Alfa GK, Chan SL
    Reply to: STRIDE's Efficacy and Safety in Asian Hepatocellular Carcinoma.
    J Hepatol. 2025 Feb 28:S0168-8278(25)00146-1. doi: 10.1016/j.jhep.2025.
    >> Share

  138. NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al
    Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
    J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025.
    >> Share

  139. YOUNOSSI ZM, Stepanova M
    Corrigendum to: 'Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease' [J Hepatol 80 (2024) 419-430].
    J Hepatol. 2025 Feb 22:S0168-8278(25)00037-6. doi: 10.1016/j.jhep.2025.
    >> Share

  140. HOFER BS, Kwanten WJ, Francque S
    Correspondence on "Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD" - Authors' Reply.
    J Hepatol. 2025 Feb 20:S0168-8278(25)00098-4. doi: 10.1016/j.jhep.2025.
    >> Share

  141. LOHSE AW, Kamath PS, Sarin SK
    The complexity of portal hypertension without (apparent) cirrhosis.
    J Hepatol. 2025 Feb 19:S0168-8278(25)00088-1. doi: 10.1016/j.jhep.2025.
    >> Share

  142. ZANETTO A, Campello E, Senzolo M, Simioni P, et al
    Response to: "Procedural bleeding in patients with cirrhosis: from prediction towards prevention".
    J Hepatol. 2025 Feb 19:S0168-8278(25)00087-X. doi: 10.1016/j.jhep.2025.
    >> Share

  143. MA AT, Juanola A, Sole C, Gines P, et al
    Revisiting the use of albumin in patients with cirrhosis - trial design matters.
    J Hepatol. 2025 Feb 19:S0168-8278(25)00086-8. doi: 10.1016/j.jhep.2025.
    >> Share

  144. NI HM, Ding WX
    An ER Transmembrane Protein Protects Against Hepatic Ischemia-Reperfusion Injury By Inhibiting ER-phagy and Apoptosis?
    J Hepatol. 2025 Feb 19:S0168-8278(25)00094-7. doi: 10.1016/j.jhep.2025.
    >> Share

  145. LIU Z, Wei S, Jiang Y, Su W, et al
    Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway.
    J Hepatol. 2025 Feb 11:S0168-8278(25)00079-0. doi: 10.1016/j.jhep.2025.
    >> Share

  146. BERTHIER A, Gheeraert C, Vinod M, Johanns M, et al
    Unveiling the Molecular Legacy of Transient Insulin Resistance: Implications for Hepatic Metabolic Adaptability.
    J Hepatol. 2025 Feb 11:S0168-8278(25)00080-7. doi: 10.1016/j.jhep.2025.
    >> Share

  147. MARTI-AGUADO D, Calleja JL, Bataller R, Crespo J, et al
    Reply to: "The HDL criterion for MetALD can misclassify patients with cirrhosis".
    J Hepatol. 2025 Feb 4:S0168-8278(25)00057-1. doi: 10.1016/j.jhep.2025.
    >> Share

  148. XUE X, Liu R, Cai Y, Gong L, et al
    Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m(6)A-regulated expression of a novel anti-fibrotic target ETV4.
    J Hepatol. 2025 Feb 4:S0168-8278(25)00055-8. doi: 10.1016/j.jhep.2025.
    >> Share

  149. XU M, Zhao J, Zhu L, Ge C, et al
    Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.
    J Hepatol. 2025;82:277-300.
    >> Share

  150. MARKOVIC J, Li R, Khanal R, Peng Q, et al
    Identification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis.
    J Hepatol. 2025;82:301-314.
    >> Share

  151. ROSENSTENGLE C, Serper M, Asrani SK, Bittermann T, et al
    Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal.
    J Hepatol. 2025;82:268-276.
    >> Share

  152. LIU YJ, Kimura M, Li X, Sulc J, et al
    ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.
    J Hepatol. 2025;82:174-188.
    >> Share

  153. MUNTER D, de Faria FW, Richter M, Aranda-Pardos I, et al
    Multiomic analysis uncovers a continuous spectrum of differentiation and Wnt-MDK-driven immune evasion in hepatoblastoma.
    J Hepatol. 2025 Feb 1:S0168-8278(25)00068-6. doi: 10.1016/j.jhep.2025.
    >> Share

  154. HAN Y, Tang J, Hu P, Ren H, et al
    Metabolic dysfunction-associated steatotic liver disease may increase intrahepatic interferon gene signatures in patients with chronic hepatitis B.
    J Hepatol. 2025 Feb 1:S0168-8278(25)00073-X. doi: 10.1016/j.jhep.2025.
    >> Share

    January 2025
  155. ZHANG Z, Geng C, Song M, Liang H, et al
    Loss of SGK1 supports metastatic colonization in hepatocellular carcinoma by promoting resistance to T cell-mediated immunity.
    J Hepatol. 2025 Jan 30:S0168-8278(25)00064-9. doi: 10.1016/j.jhep.2025.
    >> Share

  156. PUGLIESE N, De Nicola S, di Tommaso L, Aghemo A, et al
    Beyond Portal Hypertension: Characterizing Porto-Sinusoidal Vascular Disorder in Patients without signs of PH.
    J Hepatol. 2025 Jan 29:S0168-8278(25)00058-3. doi: 10.1016/j.jhep.2025.
    >> Share

  157. VITTON V, Ouafik L, Nguyen K
    HEPATIC NODULE AND RISING AFP LEVELS: COULD IT INDICATE A BENIGN CONDITION?
    J Hepatol. 2025 Jan 29:S0168-8278(25)00056-X. doi: 10.1016/j.jhep.2025.
    >> Share

  158. SALEM R, Padia SA, Toskich BB, Callahan JD, et al
    Radiation Segmentectomy for Early Hepatocellular Carcinoma is Curative.
    J Hepatol. 2025 Jan 22:S0168-8278(25)00011-X. doi: 10.1016/j.jhep.2025.
    >> Share

  159. YU H, Wang C, Qian B, Yin B, et al
    GRINA alleviates hepatic ischemia?reperfusion injury-induced apoptosis and ER-phagy by enhancing HRD1-mediated ATF6 ubiquitination.
    J Hepatol. 2025 Jan 22:S0168-8278(25)00019-4. doi: 10.1016/j.jhep.2025.
    >> Share

  160. ZHU S, Liao L, Zhong Y, Liu Z, et al
    Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis.
    J Hepatol. 2025 Jan 22:S0168-8278(25)00014-5. doi: 10.1016/j.jhep.2025.
    >> Share

  161. PINATO DJ
    Tertiary lymphoid structure dynamics at the centre of immunotherapy response in hepatocellular carcinoma.
    J Hepatol. 2025 Jan 21:S0168-8278(24)02831-9. doi: 10.1016/j.jhep.2024.
    >> Share

  162. RATZIU V, Tacke F
    The Journal of Hepatology: A new team at 40.
    J Hepatol. 2025 Jan 16:S0168-8278(25)00004-2. doi: 10.1016/j.jhep.2025.
    >> Share

  163. BARB D, Kalavalapalli S, Leiva EG, Bril F, et al
    Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.
    J Hepatol. 2025 Jan 15:S0168-8278(25)00002-9. doi: 10.1016/j.jhep.2024.
    >> Share

  164. LISMAN T
    Procedural bleeding in patients with cirrhosis: from prediction towards prevention.
    J Hepatol. 2025 Jan 11:S0168-8278(25)00010-8. doi: 10.1016/j.jhep.2025.
    >> Share

  165. RUDLER M
    Primary prophylaxis of acute variceal bleeding in patients with severe cirrhosis: Time for combination therapy?
    J Hepatol. 2025 Jan 11:S0168-8278(24)02773-9. doi: 10.1016/j.jhep.2024.
    >> Share

  166. GENG A, Brenig RG, Roux J, Lutge M, et al
    Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges.
    J Hepatol. 2025 Jan 10:S0168-8278(24)02818-6. doi: 10.1016/j.jhep.2024.
    >> Share

  167. BAJAJ JS, Fagan A, Gavis EA, Sterling RK, et al
    Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.
    J Hepatol. 2025 Jan 10:S0168-8278(25)00005-4. doi: 10.1016/j.jhep.2024.
    >> Share

  168. DEGASPERI E, Anolli MP, Jachs M, Reiberger T, et al
    Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
    J Hepatol. 2025 Jan 8:S0168-8278(25)00001-7. doi: 10.1016/j.jhep.2024.
    >> Share

  169. GADD VL, Ferreira-Gonzalez S, Man TY, Kilpatrick AM, et al
    Host hepatocyte senescence determines the success of hepatocyte transplantation in a mouse model of liver injury.
    J Hepatol. 2025 Jan 2:S0168-8278(24)02830-7. doi: 10.1016/j.jhep.2024.
    >> Share

  170. CROUCHET E, Dachraoui M, Juhling F, Roehlen N, et al
    Targeting the liver clock improves fibrosis by restoring TGF-beta signaling.
    J Hepatol. 2025;82:120-133.
    >> Share

  171. HARRISON SA, Browne SK, Suschak JJ, Tomah S, et al
    Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
    J Hepatol. 2025;82:7-17.
    >> Share

  172. REZAEE-ZAVAREH MS, Yeo YH, Wang T, Guo Z, et al
    Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    J Hepatol. 2025;82:107-119.
    >> Share

  173. KRENDL FJ, Cardini B, Zoller H, Schneeberger S, et al
    Leveraging normothermic liver machine perfusion as a platform for oncologic assessment in cirrhotic livers.
    J Hepatol. 2025;82:e12-e14.
    >> Share

    December 2024
  174. SHIN H, Hur MH, Song BG, Park SY, et al
    AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B.
    J Hepatol. 2024 Dec 20:S0168-8278(24)02784-3. doi: 10.1016/j.jhep.2024.
    >> Share

  175. GANNE-CARRIE N, Nahon P
    Differences between hepatocellular carcinoma caused by alcohol and other aetiologies.
    J Hepatol. 2024 Dec 20:S0168-8278(24)02817-4. doi: 10.1016/j.jhep.2024.
    >> Share

  176. CAPPUYNS S, Pique-Gili M, Esteban-Fabro R, Philips G, et al
    Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
    J Hepatol. 2024 Dec 19:S0168-8278(24)02771-5. doi: 10.1016/j.jhep.2024.
    >> Share

  177. IM GY, Bibireddy A, Rath S
    The HDL criterion for MetALD can misclassify patients with cirrhosis.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02781-8. doi: 10.1016/j.jhep.2024.
    >> Share

  178. FORTEA JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, et al
    Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02772-7. doi: 10.1016/j.jhep.2024.
    >> Share


  179. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.
    J Hepatol. 2024 Dec 16:S0168-8278(24)02508-X. doi: 10.1016/j.jhep.2024.
    >> Share

  180. ENGELMANN C
    Rifaximin in cirrhosis: Is its microbiological spotless record under threat?
    J Hepatol. 2024 Dec 16:S0168-8278(24)02735-1. doi: 10.1016/j.jhep.2024.
    >> Share

  181. ZANETTO A, Campello E, Bulato C, Willems R, et al
    Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis.
    J Hepatol. 2024 Dec 11:S0168-8278(24)02762-4. doi: 10.1016/j.jhep.2024.
    >> Share

  182. GUAN Y, Huang Q
    Correspondence on "Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD".
    J Hepatol. 2024 Dec 4:S0168-8278(24)02750-8. doi: 10.1016/j.jhep.2024.
    >> Share

  183. DUIJZER R, Gevers TJ, Drenth JP
    Response to: Highlighting the Impact of Hormonal Factors on Hepatic Cystogenesis: Implications for Pathophysiology and Clinical Practice.
    J Hepatol. 2024 Dec 4:S0168-8278(24)02748-X. doi: 10.1016/j.jhep.2024.
    >> Share

  184. MARTI-AGUADO D, Calleja JL, Vilar-Gomez E, Iruzubieta P, et al
    Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024;81:930-940.
    >> Share

  185. AHMED A, Cule M, Bell JD, Sattar N, et al
    Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer.
    J Hepatol. 2024;81:921-929.
    >> Share

  186. BATTISTELLA S, Piazza F, Pizzi M, Zanella S, et al
    From shadows to light: An unusual case of a hepatic mass.
    J Hepatol. 2024;81:e261-e263.
    >> Share

  187. ANGELI P
    My last Editorial as Editor-in-Chief of the Journal of Hepatology.
    J Hepatol. 2024;81:918-920.
    >> Share

  188. WANG T, Chen K, Yao W, Zheng R, et al
    Retraction notice to "Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance" [J Hepatol 74 (5) 2021 1038-1052].
    J Hepatol. 2024;81:1100.
    >> Share

    November 2024
  189. DONGELMANS EJ, Janssen HLA
    Reply to "The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.".
    J Hepatol. 2024 Nov 29:S0168-8278(24)02746-6. doi: 10.1016/j.jhep.2024.
    >> Share

  190. HAMADAH A, Gharaibeh K
    Inclusion of Patients with Active Urinary Sediment in Treatment of Hepatorenal Syndrome.
    J Hepatol. 2024 Nov 29:S0168-8278(24)02743-0. doi: 10.1016/j.jhep.2024.
    >> Share

  191. MEHAL WZ, Schwabe RF
    Corrigendum to: "A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease" [J Hepatol (2022) 765-767].
    J Hepatol. 2024 Nov 22:S0168-8278(24)02623-0. doi: 10.1016/j.jhep.2024.
    >> Share

  192. WANG Y, Hong S, Hudson H, Kory N, et al
    PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis.
    J Hepatol. 2024 Nov 14:S0168-8278(24)02707-7. doi: 10.1016/j.jhep.2024.
    >> Share

  193. LIU Y, Wei Y, Chen X, Huang S, et al
    Genetic study of intrahepatic cholestasis of pregnancy in Chinese women unveils East Asian etiology linked to historic HBV epidemic.
    J Hepatol. 2024 Nov 13:S0168-8278(24)02708-9. doi: 10.1016/j.jhep.2024.
    >> Share

  194. VANDERSCHUEREN E, Wim Laleman
    Non-invasive algorithms could outperform HVPG in selecting candidates for non-selective beta-blockers in cirrhosis.
    J Hepatol. 2024 Nov 13:S0168-8278(24)02711-9. doi: 10.1016/j.jhep.2024.
    >> Share

  195. HENGSTLER JG, Vartak N
    Activating hepatobiliary water channels for gallstone prevention in complicated gallstone disease.
    J Hepatol. 2024 Nov 12:S0168-8278(24)02704-1. doi: 10.1016/j.jhep.2024.
    >> Share

  196. GONZALEZ FJ, Xia Y
    Adipose triglyceride lipase as a target for treatment of metabolic dysfunction-associated steatohepatitis: the role of hepatic and intestinal PPARalpha.
    J Hepatol. 2024 Nov 12:S0168-8278(24)02703-X. doi: 10.1016/j.jhep.2024.
    >> Share

  197. HUR MH, Lee JH
    Reply to "A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?".
    J Hepatol. 2024 Nov 8:S0168-8278(24)02700-4. doi: 10.1016/j.jhep.2024.
    >> Share

  198. MON HC, Huang YH
    Reply to "Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?" and "Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B".
    J Hepatol. 2024 Nov 8:S0168-8278(24)02701-6. doi: 10.1016/j.jhep.2024.
    >> Share

  199. KIM HY, Rosenthal SB, Liu X, Miciano C, et al
    Multi-Modal Analysis of human Hepatic Stellate Cells identifies novel therapeutic targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Hepatol. 2024 Nov 8:S0168-8278(24)02667-9. doi: 10.1016/j.jhep.2024.
    >> Share

  200. MEHAL WZ
    Corrigendum to: "From mice to humans: Unravelling the genetic levers of NASH" [J Hepatol (2020) 749-751].
    J Hepatol. 2024 Nov 7:S0168-8278(24)02619-9. doi: 10.1016/j.jhep.2024.
    >> Share

  201. MUCINSKI JM, Salvador AF, Moore MP, Fordham TM, et al
    Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH.
    J Hepatol. 2024;81:781-793.
    >> Share

  202. HARRISON SA, Dubourg J
    Liver biopsy evaluation in MASH drug development: Think thrice, act wise.
    J Hepatol. 2024;81:886-894.
    >> Share

  203. OH JH, Ahn SB, Cho S, Nah EH, et al
    Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort.
    J Hepatol. 2024;81:772-780.
    >> Share

    October 2024
  204. OSMANI Z, Brouwer WP, Grashof DGB, Lim Y, et al
    Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in patients with chronic hepatitis B.
    J Hepatol. 2024 Oct 26:S0168-8278(24)02653-9. doi: 10.1016/j.jhep.2024.
    >> Share

  205. CAO Z, Yao Y, Cai M, Zhang C, et al
    Blood markers for type-1,-2, and -3 inflammation are associated with severity of acutely decompensated cirrhosis.
    J Hepatol. 2024 Oct 25:S0168-8278(24)02649-7. doi: 10.1016/j.jhep.2024.
    >> Share

  206. NADIM MK, Kellum JA, Durand F
    Reply to correspondence on "Acute kidney Injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting".
    J Hepatol. 2024 Oct 23:S0168-8278(24)02646-1. doi: 10.1016/j.jhep.2024.
    >> Share

  207. SAMUEL D
    EASL Clinical Practice Guidelines on liver transplantation.
    J Hepatol. 2024 Oct 23:S0168-8278(24)02440-1. doi: 10.1016/j.jhep.2024.
    >> Share

  208. LEE S, Arefaine B, Begum N, Stamouli M, et al
    Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial.
    J Hepatol. 2024 Oct 22:S0168-8278(24)02635-7. doi: 10.1016/j.jhep.2024.
    >> Share

  209. MEHAL WZ
    Corrigendum to: "A gold mine of information from a deep dive into the liver transcriptome" [J Hepatol (2024) 540-542].
    J Hepatol. 2024 Oct 22:S0168-8278(24)02620-5. doi: 10.1016/j.jhep.2024.
    >> Share

  210. LIU YC, Liaw YF
    The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.
    J Hepatol. 2024 Oct 18:S0168-8278(24)02638-2. doi: 10.1016/j.jhep.2024.
    >> Share

  211. RATZIU V, Scanlan TS, Bruinstroop E
    Thyroid hormone receptor-beta analogs for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).
    J Hepatol. 2024 Oct 18:S0168-8278(24)02639-4. doi: 10.1016/j.jhep.2024.
    >> Share

  212. XIAO G, Ren H
    Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B.
    J Hepatol. 2024 Oct 16:S0168-8278(24)02630-8. doi: 10.1016/j.jhep.2024.
    >> Share

  213. HUANG Q, Qadri SF, Bian H, Yi X, et al
    A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease.
    J Hepatol. 2024 Oct 16:S0168-8278(24)02636-9. doi: 10.1016/j.jhep.2024.
    >> Share

  214. ZHONG X, Ott M, Sharma AD, Balakrishnan A, et al
    MicroRNA-107 - a small RNA with a big impact on cytokinesis in hepatocellular carcinoma.
    J Hepatol. 2024 Oct 11:S0168-8278(24)02624-2. doi: 10.1016/j.jhep.2024.
    >> Share

  215. LU Y, Liu Y, Zuo X, Li G, et al
    CXCL12(+) Tumor-associated Endothelial Cells Promote Immune Resistance in Hepatocellular Carcinoma.
    J Hepatol. 2024 Oct 9:S0168-8278(24)02618-7. doi: 10.1016/j.jhep.2024.
    >> Share

  216. CHEN Y, Chen HN, Wang K, Zhang L, et al
    Erratum to "Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma" [J Hepatol 70 (1) 2019 66-77].
    J Hepatol. 2024 Oct 7:S0168-8278(24)02540-6. doi: 10.1016/j.jhep.2024.
    >> Share

  217. CATANIA M, Vezzoli G, Alibrandi MTS
    Highlighting the Impact of Hormonal Factors on Hepatic Cystogenesis: Implications for Pathophysiology and Clinical Practice.
    J Hepatol. 2024 Oct 5:S0168-8278(24)02581-9. doi: 10.1016/j.jhep.2024.
    >> Share

  218. LIU Z, Shan D, Han X
    STRIDE's Efficacy and Safety in Asian Hepatocellular Carcinoma.
    J Hepatol. 2024 Oct 5:S0168-8278(24)02582-0. doi: 10.1016/j.jhep.2024.
    >> Share

  219. TALANIAN M, Almeqdadi M, Chen HH
    From dark bile to bright insight: A liver biopsy with advanced fibrosis and severe cholestasis.
    J Hepatol. 2024;81:e147-e150.
    >> Share

  220. NAULT JC, Calderaro J, Ronot M
    Integration of new technologies in the multidisciplinary approach to primary liver tumours: The next-generation tumour board.
    J Hepatol. 2024;81:756-762.
    >> Share

  221. TONON M, Barone A, Calvino V, Santori V, et al
    Reply to: correspondance on "A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis".
    J Hepatol. 2024;81:e170-e171.
    >> Share

  222. DE A, Mehta M, Duseja A
    Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: An analysis of the Indian Consortium on MASLD (ICOM-D) cohort.
    J Hepatol. 2024;81:e162-e164.
    >> Share

  223. HENRY L, Paik JM, Younossi ZM
    Reply to: Correspondence on "clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease'.
    J Hepatol. 2024;81:e160-e161.
    >> Share

  224. GAWRIEH S, Vilar-Gomez E, Wilson LA, Pike F, et al
    Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.
    J Hepatol. 2024;81:600-608.
    >> Share

  225. SEGOVIA-ZAFRA A, Villanueva-Paz M, Serras AS, Matilla-Cabello G, et al
    Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network.
    J Hepatol. 2024;81:630-640.
    >> Share

  226. YOUNOSSI ZM, Kremer AE, Swain MG, Jones D, et al
    Assessment of fatigue and its impact in chronic liver disease.
    J Hepatol. 2024;81:726-742.
    >> Share

  227. LU Z, Shao W, Song J
    The transition from NAFLD to MASLD and its impact on clinical practice and outcomes.
    J Hepatol. 2024;81:e155-e156.
    >> Share

  228. LIU Y, Tan L
    An in-depth exploration of difference and similarity between NAFLD and MASLD.
    J Hepatol. 2024;81:e153-e154.
    >> Share

  229. ZHOU XD, Lonardo A, Pan CQ, Shapiro MD, et al
    Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both.
    J Hepatol. 2024;81:e157-e159.
    >> Share

    September 2024
  230. FUCHS CD, Simbrunner B, Baumgartner M, Campell C, et al
    Bile acid metabolism and signaling in liver disease.
    J Hepatol. 2024 Sep 28:S0168-8278(24)02572-8. doi: 10.1016/j.jhep.2024.
    >> Share

  231. HUO X, Yu Z, Zhao F, Chen Y, et al
    Hepatocyte Aquaporin 8-mediated Water Transport Facilitates Bile Dilution and Prevents Gallstone Formation in Mice.
    J Hepatol. 2024 Sep 24:S0168-8278(24)02563-7. doi: 10.1016/j.jhep.2024.
    >> Share

  232. LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al
    AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients after Successful Direct-Acting Antiviral Treatment.
    J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024.
    >> Share

  233. XIAO G, Ren H
    A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?
    J Hepatol. 2024 Sep 19:S0168-8278(24)02556-X. doi: 10.1016/j.jhep.2024.
    >> Share

  234. REZAEE-ZAVAREH MS, Guo Z, Yang JD
    Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries.
    J Hepatol. 2024 Sep 19:S0168-8278(24)02558-3. doi: 10.1016/j.jhep.2024.
    >> Share

  235. DAJTI E, Villanueva C, Berzigotti A, Brujats A, et al
    Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: a post-hoc analysis of the PREDESCI trial.
    J Hepatol. 2024 Sep 18:S0168-8278(24)02553-4. doi: 10.1016/j.jhep.2024.
    >> Share

  236. RIMBERT A, Wargny M, Cariou B
    Reply to "The association between primary hypobetalipoproteinemia and hepatic diseases: evidence from genetic studies".
    J Hepatol. 2024 Sep 17:S0168-8278(24)02549-2. doi: 10.1016/j.jhep.2024.
    >> Share

  237. ZHANG XP, Hu MG, Liu R
    Recognizing Significant Role of Microvascular Invasion in Postoperative Aggressive Recurrence of Early Hepatocellular Carcinoma.
    J Hepatol. 2024 Sep 17:S0168-8278(24)02548-0. doi: 10.1016/j.jhep.2024.
    >> Share

  238. TABRIZIAN P, Holzner M, Ajmera V, Kim AK, et al
    Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study.
    J Hepatol. 2024 Sep 8:S0168-8278(24)02541-8. doi: 10.1016/j.jhep.2024.
    >> Share

  239. MYOTERI D, Grypari IM, Schina M, Lohse A, et al
    An overweight female with a history of allergies and drug-induced liver injury.
    J Hepatol. 2024;81:e93-e95.
    >> Share

  240. CANCADO GGL, Deeb M, Dodington D, Hirschfield GM, et al
    The liver in haematologic oncologic disorders.
    J Hepatol. 2024;81:577-579.
    >> Share


  241. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    J Hepatol. 2024;81:492-542.
    >> Share

  242. WARGNY M, Cariou B
    Reply to: "Primary hypobetalipoproteinemia as a risk factor for liver complications".
    J Hepatol. 2024;81:e125-e126.
    >> Share

  243. GAO J, Lan T, Kostallari E, Guo Y, et al
    Angiocrine signaling in sinusoidal homeostasis and liver diseases.
    J Hepatol. 2024;81:543-561.
    >> Share

  244. KWAN AC, Wang M, Trivedi HD, Ji H, et al
    Sex-specific associations of steatotic liver disease with vascular health.
    J Hepatol. 2024;81:e105-e107.
    >> Share

  245. RONOT M
    Improving HCC surveillance with abbreviated MRI: A call to integrate and innovate?
    J Hepatol. 2024;81:376-378.
    >> Share

  246. HE L, Zheng W, Liao Y, Kong W, et al
    Individuals with cardiometabolic risk factors are at higher risk for early-onset NAFLD.
    J Hepatol. 2024;81:e99-e101.
    >> Share

  247. CILLO U, Nalesso F, Bertacco A, Indraccolo S, et al
    Normothermic perfusion of a human tumoral liver for 17 days with concomitant extracorporeal blood purification therapy: Case description.
    J Hepatol. 2024;81:e96-e98.
    >> Share

  248. KIM DH, Yoon JH, Choi MH, Lee CH, et al
    Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC.
    J Hepatol. 2024;81:461-470.
    >> Share

  249. BERTOLINI A, Nguyen M, Zehra SA, Taleb SA, et al
    Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.
    J Hepatol. 2024;81:429-440.
    >> Share

  250. TAN MY, Zhai XL
    Primary hypobetalipoproteinemia as a risk factor for liver complications.
    J Hepatol. 2024;81:e124.
    >> Share

  251. SHAN D
    Expanding the dialogue: A closer look at AIH management and HCC risk.
    J Hepatol. 2024;81:e129-e130.
    >> Share

    August 2024
  252. DONGELMANS EJ, Hirode G, Hansen BE, Chen CH, et al
    Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study).
    J Hepatol. 2024 Aug 31:S0168-8278(24)02493-0. doi: 10.1016/j.jhep.2024.
    >> Share

  253. KAHL S, Strassburger K, Pacini G, Trinks N, et al
    Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity.
    J Hepatol. 2024 Aug 30:S0168-8278(24)02490-5. doi: 10.1016/j.jhep.2024.
    >> Share

  254. TORRES S, El Maimouni C, Herrera G, Fernandez J, et al
    SPONTANEOUS CANDIDEMIA, A REAL INFECTION IN ADVANCED CIRRHOSIS.
    J Hepatol. 2024 Aug 30:S0168-8278(24)02499-1. doi: 10.1016/j.jhep.2024.
    >> Share

  255. LV Y, Wang Q, Luo B, Bai W, et al
    Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding: a prospective cohort study.
    J Hepatol. 2024 Aug 22:S0168-8278(24)02485-1. doi: 10.1016/j.jhep.2024.
    >> Share

  256. MAGAZ M, Giudicelli-Lett H, G Abraldes J, Nicoara-Farcau O, et al
    Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.
    J Hepatol. 2024 Aug 22:S0168-8278(24)02481-4. doi: 10.1016/j.jhep.2024.
    >> Share

  257. CUI A, Chung RT, Alatrakchi N
    Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance - Reply.
    J Hepatol. 2024 Aug 19:S0168-8278(24)02474-7. doi: 10.1016/j.jhep.2024.
    >> Share

  258. RAVANBAKHSH N, Genyk Y, Cheng A, Vats D, et al
    Biliary Cirrhosis associated with WDR19-Related Ciliopathy in Siblings.
    J Hepatol. 2024 Aug 18:S0168-8278(24)02475-9. doi: 10.1016/j.jhep.2024.
    >> Share

  259. YAO X, Song H, Shu H, Song J, et al
    Asymptomatic cirrhosis in a 35-year-old female.
    J Hepatol. 2024;81:e65-e67.
    >> Share

  260. TONON M, Barone A, Angeli P
    Reply to: Correspondence on "A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis".
    J Hepatol. 2024;81:e74-e75.
    >> Share

  261. DIAZ LA, Fuentes-Lopez E, Arab JP
    Reply to: "The synergism of public health policies and social work may reduce mortality from cancer, liver disease and cardiovascular disease".
    J Hepatol. 2024;81:e78-e79.
    >> Share

  262. PAN Z, Eslam M
    The MASLD criteria overlook a number of adolescent patients with severe steatosis.
    J Hepatol. 2024;81:e80-e81.
    >> Share

  263. KULKARNI AV, Sarin SK
    Acute-on-chronic liver failure - steps towards harmonization of the definition!
    J Hepatol. 2024;81:360-366.
    >> Share

  264. THIELE M, Villesen IF, Niu L, Johansen S, et al
    Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases.
    J Hepatol. 2024;81:345-359.
    >> Share

  265. CASTERA L, Garteiser P, Laouenan C, Vidal-Trecan T, et al
    Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    J Hepatol. 2024;81:195-206.
    >> Share

  266. DE HAAN J, Termorshuizen F, de Keizer N, Gommers D, et al
    One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands.
    J Hepatol. 2024;81:238-247.
    >> Share

  267. GUO S, Zeng J
    The synergism of public health policies and social work may reduce mortality from cancer, liver disease and cardiovascular disease.
    J Hepatol. 2024;81:e76-e77.
    >> Share

    July 2024
  268. LAU G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, et al
    Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
    J Hepatol. 2024 Jul 30:S0168-8278(24)02424-3. doi: 10.1016/j.jhep.2024.
    >> Share

  269. VENZIN V, Beccaria CG, Andreata F, Fumagalli V, et al
    Intrahepatic immunity to hepatitis B virus.
    J Hepatol. 2024 Jul 30:S0168-8278(24)00364-7. doi: 10.1016/j.jhep.2024.
    >> Share

  270. TONON M, Barone A, Angeli P
    Reply to: Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
    J Hepatol. 2024 Jul 29:S0168-8278(24)02434-6. doi: 10.1016/j.jhep.2024.
    >> Share

  271. MA AT, Juanola A, Sole C, Gines P, et al
    Shortening the albumin challenge from 48 to 24 hours may lead to overdiagnosis of hepatorenal syndrome-acute kidney injury and overtreatment with terlipressin.
    J Hepatol. 2024 Jul 29:S0168-8278(24)02422-X. doi: 10.1016/j.jhep.2024.
    >> Share

  272. DI COLA S, D'Amico G, Merli M
    Reply to "Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations ".
    J Hepatol. 2024 Jul 11:S0168-8278(24)02353-5. doi: 10.1016/j.jhep.2024.
    >> Share

  273. ARTRU F, Sacleux SC, Ursic-Bedoya J, Ntandja Wandji LC, et al
    Long-term outcome following liver transplantation of patients with ACLF grade 3.
    J Hepatol. 2024 Jul 7:S0168-8278(24)02346-8. doi: 10.1016/j.jhep.2024.
    >> Share

  274. KWON Y, Gottmann P, Wang S, Tissink J, et al
    Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024 Jul 6:S0168-8278(24)02347-X. doi: 10.1016/j.jhep.2024.
    >> Share

  275. RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
    Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
    J Hepatol. 2024;81:e20-e21.
    >> Share

  276. CUSI K, Younossi Z, Roden M
    From NAFLD to MASLD: Promise and pitfalls of a new definition.
    J Hepatol. 2024;81:e18-e19.
    >> Share

  277. HE S, Luo Y, Ma W, Wang X, et al
    Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis.
    J Hepatol. 2024;81:135-148.
    >> Share

  278. THORHAUGE KH, Semmler G, Johansen S, Lindvig KP, et al
    Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
    J Hepatol. 2024;81:23-32.
    >> Share

    June 2024
  279. MENDOZA YP, Tsouka S, Semmler G, Seubnooch P, et al
    Metabolic phenotyping of patients with Advanced Chronic Liver Disease for better characterization of Cirrhosis Regression.
    J Hepatol. 2024 Jun 27:S0168-8278(24)02334-1. doi: 10.1016/j.jhep.2024.
    >> Share

  280. ROONEY M, Duduskar SN, Ghait M, Reissing J, et al
    Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release upon infection.
    J Hepatol. 2024 Jun 25:S0168-8278(24)02325-0. doi: 10.1016/j.jhep.2024.
    >> Share

  281. ZHANG Y, Chen J, Su S
    The association between primary hypobetalipoproteinemia and hepatic Diseases: evidence from genetic studies.
    J Hepatol. 2024 Jun 24:S0168-8278(24)02328-6. doi: 10.1016/j.jhep.2024.
    >> Share

  282. FUSTER-ANGLADA C, Mauro E, Ferrer-Fabrega J, Caballol B, et al
    Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.
    J Hepatol. 2024 Jun 24:S0168-8278(24)02324-9. doi: 10.1016/j.jhep.2024.
    >> Share

  283. TARU V, Szabo G, Mehal W, Reiberger T, et al
    Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation.
    J Hepatol. 2024 Jun 20:S0168-8278(24)02322-5. doi: 10.1016/j.jhep.2024.
    >> Share

  284. PATMORE LA, Sonneveld MJ
    Reply 'Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe'.
    J Hepatol. 2024 Jun 11:S0168-8278(24)02311-0. doi: 10.1016/j.jhep.2024.
    >> Share

  285. SHAN D, Zhang G, Du Z
    Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations.
    J Hepatol. 2024 Jun 9:S0168-8278(24)02309-2. doi: 10.1016/j.jhep.2024.
    >> Share

  286. LAWITZ EJ, Fraessdorf M, Neff GW, Schattenberg JM, et al
    Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
    J Hepatol. 2024 Jun 7:S0168-8278(24)02303-1. doi: 10.1016/j.jhep.2024.
    >> Share

  287. LI M, Bhoori S, Mehta N, Mazzaferro V, et al
    Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
    J Hepatol. 2024 Jun 5:S0168-8278(24)00423-9. doi: 10.1016/j.jhep.2024.
    >> Share

  288. COLAPIETRO F, Akpinar R, Pugliese N, Di Tommaso L, et al
    Unexpected diagnosis in females with abnormal liver ultrasound.
    J Hepatol. 2024;80:e243-e245.
    >> Share

  289. DUIJZER R, Boerrigter MM, Gevers TJG, Drenth JPH, et al
    The pathophysiology of polycystic liver disease.
    J Hepatol. 2024;80:981-983.
    >> Share

  290. BROUWERS MCGJ, Cassiman D
    Rare monogenic causes of steatotic liver disease masquerading as MASLD.
    J Hepatol. 2024;80:e252-e253.
    >> Share

  291. HASHIDA R, Nakano D, Kawaguchi M, Younossi ZM, et al
    Changing from NAFLD to MASLD: The implications for health-related quality of life data.
    J Hepatol. 2024;80:e249-e251.
    >> Share

  292. NORMAN JS, Mehta N
    Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
    J Hepatol. 2024;80:e273-e274.
    >> Share

  293. DAI H, Zhu C, Huai Q, Xu W, et al
    Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.
    J Hepatol. 2024;80:913-927.
    >> Share

  294. WU XN, Wang MZ, Zhang N, Zhang W, et al
    Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
    J Hepatol. 2024;80:928-940.
    >> Share

  295. ZOU Z, Liu X, Yu J, Ban T, et al
    Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    J Hepatol. 2024;80:834-845.
    >> Share

  296. CABIBBO G, Celsa C, Rimassa L, Torres F, et al
    Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice.
    J Hepatol. 2024;80:957-966.
    >> Share

  297. PANG Y, Aberg F, Chen Z, Li L, et al
    Predicting risk of chronic liver disease in Chinese adults: External validation of the CLivD score.
    J Hepatol. 2024;80:e264-e266.
    >> Share

  298. HE C, Lu D, Zheng S, Xu X, et al
    Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
    J Hepatol. 2024;80:e287-e288.
    >> Share

  299. ZHANG Y, Liu H, Sheng B, Tham YC, et al
    Preliminary fatty liver disease grading using general-purpose online large language models: ChatGPT-4 or Bard?
    J Hepatol. 2024;80:e279-e281.
    >> Share

  300. VARGHESE J, Chapiro J
    ChatGPT: The transformative influence of generative AI on science and healthcare.
    J Hepatol. 2024;80:977-980.
    >> Share

    May 2024
  301. LAO Y, Cui X, Xu Z, Yan H, et al
    Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma.
    J Hepatol. 2024 May 31:S0168-8278(24)00369-6. doi: 10.1016/j.jhep.2024.
    >> Share

  302. PATERNOSTRO R, Kwanten WJ, Hofer BS, Semmler G, et al
    Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
    J Hepatol. 2024 May 30:S0168-8278(24)00368-4. doi: 10.1016/j.jhep.2024.
    >> Share


  303. EASL Clinical Practice Guidelines on genetic cholestatic liver diseases.
    J Hepatol. 2024 May 29:S0168-8278(24)00274-5. doi: 10.1016/j.jhep.2024.
    >> Share

  304. MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
    Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
    >> Share

  305. ROY A, Tewari A, Sonthalia N, Chand Ghoshal U, et al
    Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
    J Hepatol. 2024 May 24:S0168-8278(24)00363-5. doi: 10.1016/j.jhep.2024.
    >> Share

  306. DI COLA S, D'Amico G, Caraceni P, Schepis F, et al
    Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
    J Hepatol. 2024 May 21:S0168-8278(24)00355-6. doi: 10.1016/j.jhep.2024.
    >> Share

  307. CHAPUS F, Giraud G, Huchon P, Roda M, et al
    Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes.
    J Hepatol. 2024 May 21:S0168-8278(24)00351-9. doi: 10.1016/j.jhep.2024.
    >> Share

  308. CHEN J, Kaya NA, Zhang Y, Kendarsari RI, et al
    A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and 'bad apple' effect on clinical trajectory.
    J Hepatol. 2024 May 21:S0168-8278(24)00352-0. doi: 10.1016/j.jhep.2024.
    >> Share

  309. COLAPIETRO F, Lleo A
    Reply: Incidence And Predictors Of Hepatocellular Carcinoma In Patients With Autoimmune Hepatitis?
    J Hepatol. 2024 May 20:S0168-8278(24)00354-4. doi: 10.1016/j.jhep.2024.
    >> Share


  310. Erratum to "EASL Clinical Practice Guidelines on acute-on-chronic liver failure" [J Hepatol 79 (2023) 461-491].
    J Hepatol. 2024 May 20:S0168-8278(24)00164-8. doi: 10.1016/j.jhep.2024.
    >> Share

  311. FRANCQUE S, Krag A, Shawcross DL, Zelber-Sagi S, et al
    A Turning point in Hepatology? EASL Reflects on the First Approved Drug for MASH.
    J Hepatol. 2024 May 16:S0168-8278(24)00340-4. doi: 10.1016/j.jhep.2024.
    >> Share

  312. ZHU CX, Yan K, Chen L, Huang RR, et al
    Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8(+) T cells in hepatocellular carcinoma.
    J Hepatol. 2024 May 15:S0168-8278(24)00342-8. doi: 10.1016/j.jhep.2024.
    >> Share

  313. NARDELLI S, Vizzutti F, Marra F, Schepis F, et al
    Can we really advise a patient undergoing TIPS that the onset of episodic hepatic encephalopathy will not influence his/her survival?
    J Hepatol. 2024 May 9:S0168-8278(24)00339-8. doi: 10.1016/j.jhep.2024.
    >> Share

  314. ZHANG Y, Xiao F, Xie R
    Healthy volunteer bias for the role of genetic risk in dietary effects on hepatic steatosis, inflammation and fibrosis.
    J Hepatol. 2024 May 9:S0168-8278(24)00335-0. doi: 10.1016/j.jhep.2024.
    >> Share

  315. YANG M, Zhang F, Liu K
    Cirrhosis Decompensation: Clinical and Prognostic Analysis from a New Perspective.
    J Hepatol. 2024 May 9:S0168-8278(24)00337-4. doi: 10.1016/j.jhep.2024.
    >> Share

  316. HARRISON SA, Rolph T, Knot M, Dubourg J, et al
    FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond.
    J Hepatol. 2024 May 4:S0168-8278(24)00332-5. doi: 10.1016/j.jhep.2024.
    >> Share

  317. ZHU B, Guo Y, Lv S, Ling X, et al
    Hepatic phenotypes of EFL1-related Shwachman-Diamond syndrome in a biopsy-validated study.
    J Hepatol. 2024 May 3:S0168-8278(24)00328-3. doi: 10.1016/j.jhep.2024.
    >> Share

  318. FOUAD Y, Ghazinyan H, Alboraie M, Al Khatry M, et al
    Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition.
    J Hepatol. 2024;80:e194-e197.
    >> Share

  319. XIAO R, Tian Y, Zhang J, Li N, et al
    Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
    J Hepatol. 2024;80:792-804.
    >> Share

  320. CHOLANKERIL G, Kanwal F
    Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea".
    J Hepatol. 2024;80:e218-e219.
    >> Share

  321. YOUNOSSI ZM, Paik JM, Stepanova M, Ong J, et al
    Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    J Hepatol. 2024;80:694-701.
    >> Share

  322. WANG Z, Xie D, Li J, Zhai Z, et al
    Molecular force-induced liberation of transforming growth factor-beta remodels the spleen for ectopic liver regeneration.
    J Hepatol. 2024;80:753-763.
    >> Share

  323. SUN Z, Liu M, Guo J, Wang S, et al
    BMI status and its changes across adulthood in relation to all-cause mortality in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024;80:e197-e199.
    >> Share

  324. XIAO MC, Jiang N, Chen LL, Liu F, et al
    TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4alpha stability.
    J Hepatol. 2024;80:778-791.
    >> Share

  325. ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
    Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
    J Hepatol. 2024;80:730-743.
    >> Share

  326. XIAO H, Niu D, Zhang B
    Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis.
    J Hepatol. 2024;80:e207-e209.
    >> Share

  327. MA D, Li X
    Methodological challenges in studying immune-suppressive neutrophils in HCC models.
    J Hepatol. 2024;80:e215-e216.
    >> Share

  328. CIARDULLO S, Perseghin G
    Steatotic liver disease phenotypes in the United States: The impact of alcohol consumption assessment.
    J Hepatol. 2024;80:e203-e204.
    >> Share

    April 2024
  329. YANG L, Niu K, Wang J, Shen W, et al
    Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00278-2. doi: 10.1016/j.jhep.2024.
    >> Share

  330. OLLIVIER-HOURMAND I, Lebedel L, Bartroli Alabau B, Goria O, et al
    Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.
    >> Share

  331. TAN MY, Su JH
    Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00287-3. doi: 10.1016/j.jhep.2024.
    >> Share

  332. MCGETTIGAN B, Shah V
    EVERY SHERIFF NEEDS A DEPUTY: TARGETING NON-PARENCHYMAL CELLS TO TREAT HEPATIC FIBROSIS.
    J Hepatol. 2024 Apr 25:S0168-8278(24)00283-6. doi: 10.1016/j.jhep.2024.
    >> Share

  333. FU JT, Liu J, Wu WB, Chen YT, et al
    Targeting EFHD2 Inhibits Interferon-gamma Signaling and Ameliorates Non-Alcoholic Steatohepatitis.
    J Hepatol. 2024 Apr 24:S0168-8278(24)00277-0. doi: 10.1016/j.jhep.2024.
    >> Share

  334. CHEN K, Wang Y, Yang J, Kloting N, et al
    EMC10 modulates hepatic ER stress and steatosis in an isoform specific manner.
    J Hepatol. 2024 Apr 8:S0168-8278(24)00234-4. doi: 10.1016/j.jhep.2024.
    >> Share

  335. YIN K, Buttner M, Deligiannis IK, Strzelecki M, et al
    Polyploidisation pleiotropically buffers ageing in hepatocytes.
    J Hepatol. 2024 Apr 5:S0168-8278(24)00227-7. doi: 10.1016/j.jhep.2024.
    >> Share

  336. CHEN VL, Du X, Oliveri A, Chen Y, et al
    Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.
    J Hepatol. 2024 Apr 4:S0168-8278(24)00230-7. doi: 10.1016/j.jhep.2024.
    >> Share

  337. MOGA L, Paradis V, Bruno O, Valla D, et al
    Hepatomegaly in a patient with a history of acute myeloid leukemia.
    J Hepatol. 2024;80:e139-e142.
    >> Share

  338. TREVISANI F, Vitale A, Kudo M, Kulik L, et al
    Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal.
    J Hepatol. 2024;80:661-669.
    >> Share

  339. WANG CW, Huang PC, Dai CY, Huang JF, et al
    Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD - identifying the optimal pediatric label.
    J Hepatol. 2024;80:e157-e159.
    >> Share

  340. SHIRI AM, Zhang T, Bedke T, Zazara DE, et al
    IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction.
    J Hepatol. 2024;80:634-644.
    >> Share

  341. SUZUKI H, Tanaka T, Yamaguchi S, Miwa K, et al
    Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD.
    J Hepatol. 2024;80:e150-e151.
    >> Share

  342. CHEN J, Zhou H, Liu K
    Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease.
    J Hepatol. 2024;80:e143-e145.
    >> Share

  343. RETAT L, Webber L, Jepsen P, Martin A, et al
    Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study.
    J Hepatol. 2024;80:543-552.
    >> Share

  344. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
    Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
    J Hepatol. 2024;80:586-595.
    >> Share

  345. YANG A, Zhu X, Zhang L, Ding Y, et al
    Transitioning from NAFLD to MAFLD and MASLD: Consistent prevalence and risk factors in a Chinese cohort.
    J Hepatol. 2024;80:e154-e155.
    >> Share

    March 2024
  346. HEUSCHKEL MJ, Bach C, Meiss-Heydmann L, Gerges E, et al
    Erratum to 'JAK1 promotes HDV replication and is a potential target for antiviral therapy' [J Hepatol 80 (2024) 220-231].
    J Hepatol. 2024 Mar 30:S0168-8278(24)00165-X. doi: 10.1016/j.jhep.2024.
    >> Share

  347. D'AMICO G, Perricone G
    Unaswered questions for non-acute (NAD) and acute (AD) decompensation in cirrhosis.
    J Hepatol. 2024 Mar 26:S0168-8278(24)00210-1. doi: 10.1016/j.jhep.2024.
    >> Share

  348. CHAN SL, Ryoo BY, Mo F, Chan LL, et al
    Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    J Hepatol. 2024 Mar 26:S0168-8278(24)00216-2. doi: 10.1016/j.jhep.2024.
    >> Share

  349. STRANDBERG R, Jepsen P, Hagstrom H
    Developing and Validating Clinical Prediction Models in Hepatology-an Overview for Clinicians.
    J Hepatol. 2024 Mar 24:S0168-8278(24)00213-7. doi: 10.1016/j.jhep.2024.
    >> Share

  350. PASTA A, Pieri G, Plaz Torres MC, Trevisani F, et al
    Hepatocellular carcinoma in patients with Autoimmune Hepatitis.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00208-3. doi: 10.1016/j.jhep.2024.
    >> Share

  351. NADIM MK, Kellum JA, Forni L, Francoz C, et al
    Acute kidney injury in patients with Cirrhosis: Acute disease quality Initiative (ADQI) and international Club of ascites (ICA) joint multidisciplinary consensus meeting.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00214-9. doi: 10.1016/j.jhep.2024.
    >> Share

  352. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
    Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00202-2. doi: 10.1016/j.jhep.2024.
    >> Share

  353. YASHASWINI CN, Qin T, Bhattacharya D, Amor C, et al
    Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024 Mar 18:S0168-8278(24)00197-1. doi: 10.1016/j.jhep.2024.
    >> Share

  354. XU L, Zhang Y, Lin Z, Deng X, et al
    FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    J Hepatol. 2024 Mar 18:S0168-8278(24)00199-5. doi: 10.1016/j.jhep.2024.
    >> Share

  355. MA AT, Sole C, Juanola A, Escude L, et al
    Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00157-0. doi: 10.1016/j.jhep.2024.
    >> Share

  356. JACHS M, Sandmann L, Hartl L, Tergast T, et al
    Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
    >> Share

  357. CHOI SH, Lee BM, Kim J, Kim DY, et al
    Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: A Phase II Study.
    J Hepatol. 2024 Mar 9:S0168-8278(24)00154-5. doi: 10.1016/j.jhep.2024.
    >> Share

  358. TOMLINSON JL, Li B, Yang J, Loeuillard E, et al
    Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma.
    J Hepatol. 2024 Mar 6:S0168-8278(24)00127-2. doi: 10.1016/j.jhep.2024.
    >> Share

  359. HAXHE S, Baldin P, Trefois P, Havelange V, et al
    Jaundice with severe leucocytosis.
    J Hepatol. 2024;80:e103-e105.
    >> Share

  360. RUSSO FP, Francque SM, Shawcross DL, Krag AA, et al
    Advocating for the implementation of the new nomenclature for steatotic liver disease: A call to action for the national associations.
    J Hepatol. 2024;80:384-386.
    >> Share

  361. GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
    Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
    J Hepatol. 2024;80:495-504.
    >> Share

  362. DIAZ LA, Fuentes-Lopez E, Idalsoaga F, Ayares G, et al
    Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes.
    J Hepatol. 2024;80:409-418.
    >> Share

  363. GE X, Desert R, Magdaleno F, Han H, et al
    Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
    J Hepatol. 2024;80:482-494.
    >> Share

  364. YOUNOSSI ZM, Alqahtani SA, Alswat K, Yilmaz Y, et al
    Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
    J Hepatol. 2024;80:419-430.
    >> Share

  365. BOESCH M, Lindhorst A, Feio-Azevedo R, Brescia P, et al
    Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
    J Hepatol. 2024;80:397-408.
    >> Share

  366. BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
    Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
    J Hepatol. 2024;80:467-481.
    >> Share

  367. IRUZUBIETA P, Santos-Laso A, Arias-Loste MT, Calleja JL, et al
    Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings.
    J Hepatol. 2024;80:e121-e123.
    >> Share

  368. LEE E, Korf H, Vidal-Puig A
    Reply to: "Liver-adipose tissue crosstalk in nonalcoholic fatty liver disease: the emerging role of remnant cholesterol": "BAT activation might improve NAFLD in patients, but this might require developing and/or maintaining functionally relevant level
    J Hepatol. 2024;80:e112-e114.
    >> Share

  369. LARRUE H, Bureau C, D'Amico G
    Reply to: "Comment on 'TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis'": Further decompensation should now be used as a clinically relevant outc
    J Hepatol. 2024;80:e109-e110.
    >> Share

  370. LIU Y, Chen M
    Liver-adipose tissue crosstalk in non-alcoholic fatty liver disease: The emerging role of remnant cholesterol.
    J Hepatol. 2024;80:e111-e112.
    >> Share

    February 2024
  371. XIE P, Yu M, Zhang B, Yu Q, et al
    CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
    J Hepatol. 2024 Feb 23:S0168-8278(24)00129-6. doi: 10.1016/j.jhep.2024.
    >> Share

  372. BLASZKIEWICZ J, Duncan SA
    Use of stem cell-derived hepatocytes to model liver disease.
    J Hepatol. 2024 Feb 15:S0168-8278(23)05306-0. doi: 10.1016/j.jhep.2023.
    >> Share

  373. CAON E, Martins M, Hodgetts H, Blanken L, et al
    Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
    J Hepatol. 2024 Feb 14:S0168-8278(24)00110-7. doi: 10.1016/j.jhep.2024.
    >> Share

  374. NARDELLI S, Riggio O, Marra F, Gioia S, et al
    Response to "Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: do spontaneous portosystemic shunts matter?".
    J Hepatol. 2024 Feb 14:S0168-8278(24)00122-3. doi: 10.1016/j.jhep.2024.
    >> Share

  375. DE VILLE DE GOYET J
    Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
    J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
    >> Share

  376. YANG H, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!'.
    J Hepatol. 2024 Feb 10:S0168-8278(24)00123-5. doi: 10.1016/j.jhep.2024.
    >> Share

  377. ARTRU F, Reiberger T
    One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00118-1. doi: 10.1016/j.jhep.2024.
    >> Share

  378. ALLWEISS L, Volmari A, Suri V, Wallin JJ, et al
    Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00114-4. doi: 10.1016/j.jhep.2024.
    >> Share

  379. SOIN A, Lesurtel M, Clavien PA
    To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
    J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
    >> Share

  380. HUANG CH, Tsai MH, Lin CY
    Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis.
    J Hepatol. 2024 Feb 7:S0168-8278(24)00119-3. doi: 10.1016/j.jhep.2024.
    >> Share

  381. LIU C, Guo C, Liu K
    Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance.
    J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024.
    >> Share

  382. T R, J B
    Endoscopic diagnosis and treatment for portal hypertension: not yet ready for clinical practice!
    J Hepatol. 2024 Feb 6:S0168-8278(24)00120-X. doi: 10.1016/j.jhep.2024.
    >> Share

  383. WARGNY M, Goronflot T, Rimbert A, Boursier J, et al
    Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population.
    J Hepatol. 2024 Feb 6:S0168-8278(24)00108-9. doi: 10.1016/j.jhep.2024.
    >> Share

  384. SILVA H, King JJ, Thorburn D, Luong TV, et al
    A rare cause of liver fibrosis in an adult patient.
    J Hepatol. 2024;80:e48-e50.
    >> Share

  385. ESLER WP, Cohen DE
    Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
    J Hepatol. 2024;80:362-377.
    >> Share

  386. ARORA U, Biswas S, Aggarwal S, Duseja A, et al
    MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.
    J Hepatol. 2024;80:e89-e91.
    >> Share

  387. DI SESSA A, Guarino S, Umano GR, Miraglia Del Giudice E, et al
    MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.
    J Hepatol. 2024;80:e87-e89.
    >> Share

  388. PADILLA J, Osman NM, Bissig-Choisat B, Grimm SL, et al
    Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
    J Hepatol. 2024;80:282-292.
    >> Share

  389. HE L, Zheng W, Qiu K, Kong W, et al
    Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.
    J Hepatol. 2024;80:e85-e87.
    >> Share

  390. KIM D, Wijarnpreecha K, Cholankeril G, Ahmed A, et al
    Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States.
    J Hepatol. 2024;80:e79-e81.
    >> Share

  391. JEONG S
    Nutrients associated with metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024;80:e81-e82.
    >> Share

  392. CHEN L, Tao X, Zeng M, Mi Y, et al
    Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.
    J Hepatol. 2024;80:e64-e66.
    >> Share

  393. SANAL MG
    Is the change from NAFLD to MASLD driven by political correctness?
    J Hepatol. 2024;80:e74-e76.
    >> Share

  394. HAGSTROM H, Vessby J, Ekstedt M, Shang Y, et al
    99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.
    J Hepatol. 2024;80:e76-e77.
    >> Share

  395. PERAZZO H, Pacheco AG, Griep RH
    Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort.
    J Hepatol. 2024;80:e72-e74.
    >> Share

  396. LUO N, Zhang X, Huang J, Chen H, et al
    Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020.
    J Hepatol. 2024;80:e70-e71.
    >> Share

  397. EL-KASSAS M, Alswat K
    Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time.
    J Hepatol. 2024;80:e66-e68.
    >> Share

  398. JI H, Cheng S
    Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex matters.
    J Hepatol. 2024;80:e68-e69.
    >> Share

  399. SEMMLER G, Wernly B, Datz C
    What's in a name? New nomenclature for steatotic liver disease - to be or not to be?
    J Hepatol. 2024;80:e56-e58.
    >> Share

  400. SHIPMAN KE
    Sample types and patient preparation required when adopting the new fatty liver disease nomenclature.
    J Hepatol. 2024;80:e60-e61.
    >> Share

  401. DE A, Bhagat N, Mehta M, Taneja S, et al
    Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
    J Hepatol. 2024;80:e61-e62.
    >> Share

  402. RATZIU V, Boursier J
    Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.
    J Hepatol. 2024;80:e51-e52.
    >> Share

  403. SONG SJ, Lai JC, Wong GL, Wong VW, et al
    Can we use old NAFLD data under the new MASLD definition?
    J Hepatol. 2024;80:e54-e56.
    >> Share

  404. LI M, Xie W
    Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
    J Hepatol. 2024;80:e53-e54.
    >> Share

  405. SCHNEIDER KM, Schneider CV
    A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank.
    J Hepatol. 2024;80:e58-e60.
    >> Share

  406. ZHANG Q, Wei T, Jin W, Yan L, et al
    Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    J Hepatol. 2024;80:293-308.
    >> Share

  407. LEI Z, Yu J, Wu Y, Shen J, et al
    CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis.
    J Hepatol. 2024;80:194-208.
    >> Share

    January 2024
  408. NING Z
    An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
    >> Share

  409. CAMPION D, Caviglia GP, Alessandria C
    Reply to "The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis".
    J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
    >> Share

  410. NAYAGAM JS, Miquel R, Thompson RJ, Joshi D, et al
    Genetic cholestasis in children and adults.
    J Hepatol. 2024 Jan 30:S0168-8278(23)05305-9. doi: 10.1016/j.jhep.2023.
    >> Share

  411. TANG R, Li Y, Chen R, Ma X, et al
    Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
    J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
    >> Share

  412. TABRIZIAN P, Abdelrahim M, Schwartz M
    Immunotherapy and Transplantation for Hepatocellular Carcinoma.
    J Hepatol. 2024 Jan 20:S0168-8278(24)00053-9. doi: 10.1016/j.jhep.2024.
    >> Share

  413. ESPINOZA AF, Patel RH, Patel KR, Badachhape AA, et al
    A Novel Treatment Strategy Utilizing Panobinostat for High-Risk and Treatment-Refractory Hepatoblastoma.
    J Hepatol. 2024 Jan 17:S0168-8278(24)00040-0. doi: 10.1016/j.jhep.2024.
    >> Share

  414. CHAN LL, Mok K, Chan SL
    Radiotherapy following Intrahepatic Progression on Immunotherapy in Advanced Hepatocellular Carcinoma.
    J Hepatol. 2024 Jan 17:S0168-8278(24)00044-8. doi: 10.1016/j.jhep.2024.
    >> Share

  415. OSONOI S, Takebe T
    Organoid-guided Precision Hepatology for Metabolic Liver Disease.
    J Hepatol. 2024 Jan 16:S0168-8278(24)00038-2. doi: 10.1016/j.jhep.2024.
    >> Share

  416. NAKANO M, Kawaguchi M, Kawaguchi T
    Almost Identical Values of Various Noninvasive Indexes for Hepatic Fibrosis and Steatosis between NAFLD and MASLD in Asia.
    J Hepatol. 2024 Jan 13:S0168-8278(24)00037-0. doi: 10.1016/j.jhep.2023.
    >> Share

  417. JACHS M, Hartl L, Simbrunner B, Semmler G, et al
    Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    J Hepatol. 2024 Jan 11:S0168-8278(24)00009-6. doi: 10.1016/j.jhep.2023.
    >> Share

  418. SONG Q, Zhang X, Yu J
    Reply to "Stop Using the Misidentified Cell Line - LO2 as a Human Hepatocyte".
    J Hepatol. 2024 Jan 4:S0168-8278(24)00006-0. doi: 10.1016/j.jhep.2023.
    >> Share

  419. HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
    Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
    J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
    >> Share

  420. SALOMONE F, Pipitone RM, Longo M, Malvestiti F, et al
    Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19].
    J Hepatol. 2024 Jan 4:S0168-8278(23)05355-2. doi: 10.1016/j.jhep.2023.
    >> Share

  421. TERGAST TL, Maasoumy B
    The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00001-1. doi: 10.1016/j.jhep.2023.
    >> Share

  422. ZHENG C, Wang L, Zou T, Lian S, et al
    Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8+ T cells.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00004-7. doi: 10.1016/j.jhep.2023.
    >> Share

  423. SALOMONE F, Pipitone RM, Longo M, Malvestiti F, et al
    SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2024;80:10-19.
    >> Share

  424. BALCAR L, Mandorfer M, Hernandez-Gea V, Procopet B, et al
    Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving beta-blockers+ligation to prevent re-bleeding.
    J Hepatol. 2024;80:73-81.
    >> Share

  425. THOMAIDES-BREARS H, Banerjee R, Banerjee A
    Reply to: "Reassessing the causal relationship between liver diseases and cardiovascular outcomes" and "From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank".
    J Hepatol. 2024;80:e24-e25.
    >> Share

  426. KAFFE E, Tisi A, Magkrioti C, Aidinis V, et al
    Bioactive signalling lipids as drivers of chronic liver diseases.
    J Hepatol. 2024;80:140-154.
    >> Share

  427. XIANG X, Wei Y, Zhao K
    Reassessing the causal relationship between liver diseases and cardiovascular outcomes.
    J Hepatol. 2024;80:e20-e22.
    >> Share

  428. DIAZ-FONTENLA F, Caballero-Marcos A, Peligros I, Vicario Moreno JL, et al
    Unusual early post-transplant hepatic dysfunction.
    J Hepatol. 2024;80:e11-e13.
    >> Share

    December 2023
  429. ZHANG F, Zhang M, Wang L, Zhuge Y, et al
    Hepatic encephalopathy and survival after transjugular intrahepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?
    J Hepatol. 2023 Dec 26:S0168-8278(23)05368-0. doi: 10.1016/j.jhep.2023.
    >> Share

  430. NORMAN JS, Mehta N
    Reply to: Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Dec 26:S0168-8278(23)05371-0. doi: 10.1016/j.jhep.2023.
    >> Share

  431. TONON M, D'Ambrosio R, Calvino V, Tosetti G, et al
    A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05359-X. doi: 10.1016/j.jhep.2023.
    >> Share

  432. HAHN M, Herber A, Berg T, Seehofer D, et al
    Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05357-6. doi: 10.1016/j.jhep.2023.
    >> Share

  433. LEHRICH BM, Zhang J, Monga SP, Dhanasekaran R, et al
    Battle of the Biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma.
    J Hepatol. 2023 Dec 15:S0168-8278(23)05307-2. doi: 10.1016/j.jhep.2023.
    >> Share

  434. VUKOTIC R, Di Donato R, Bosch J, Andreone P, et al
    Reply letter to the letter to the editor entitled: "5-mthf enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial: was an accurate statistical analysis performed?".
    J Hepatol. 2023 Dec 12:S0168-8278(23)05302-3. doi: 10.1016/j.jhep.2023.
    >> Share

  435. NARDELLI S, Riggio O, Marra F, Gioia S, et al
    Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
    J Hepatol. 2023 Dec 12:S0168-8278(23)05310-2. doi: 10.1016/j.jhep.2023.
    >> Share

  436. RATZIU V, Harrison SA, Hajji Y, Magnanensi J, et al
    NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
    J Hepatol. 2023 Dec 5:S0168-8278(23)05270-4. doi: 10.1016/j.jhep.2023.
    >> Share

  437. FAN W, Cao D, Yang B, Wang J, et al
    Hepatic prohibitin 1 and methionine adenosyltransferase alpha1 defend against primary and secondary liver cancer metastasis.
    J Hepatol. 2023 Dec 2:S0168-8278(23)05298-4. doi: 10.1016/j.jhep.2023.
    >> Share

  438. ZANETTO A, Senzolo M, Pelizzaro F, Mescoli C, et al
    A rare cause of painful hepatomegaly.
    J Hepatol. 2023;79:e228-e230.
    >> Share


  439. Ending stigmatizing language in alcohol and liver disease: A liver societies' statement.
    J Hepatol. 2023;79:1347-1348.
    >> Share

  440. HUTCHISON AL, Tavaglione F, Romeo S, Charlton M, et al
    Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance.
    J Hepatol. 2023;79:1524-1541.
    >> Share

  441. MOHR I, Poujois A, Ala A, Weiss KH, et al
    Reply to: "Early neurological worsening in Wilson disease: The need for an evidence-based definition".
    J Hepatol. 2023;79:e243.
    >> Share

  442. MENG Y, Ye F, Nie P, Zhao Q, et al
    Immunosuppressive CD10(+)ALPL(+) neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.
    J Hepatol. 2023;79:1435-1449.
    >> Share

  443. PETERMANN-ROCHA F, Ho FK, Pell JP
    Reply to: "Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations".
    J Hepatol. 2023;79:e233-e234.
    >> Share

  444. SIMON TG, Roelstraete B, Hagstrom H, Loomba R, et al
    Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
    J Hepatol. 2023;79:1366-1373.
    >> Share

  445. NEWSOME PN, Ambery P
    Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
    J Hepatol. 2023;79:1557-1565.
    >> Share

  446. LITWIN T, Czlonkowska A, Smolinski L
    Early neurological worsening in Wilson disease: The need for an evidence-based definition.
    J Hepatol. 2023;79:e241-e242.
    >> Share

  447. RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
    A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    J Hepatol. 2023;79:1542-1556.
    >> Share

  448. LONG L, Zhou X
    Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations.
    J Hepatol. 2023;79:e232-e233.
    >> Share

    November 2023
  449. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
    J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
    >> Share

  450. KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
    ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
    J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
    >> Share

  451. BERASAIN C
    When you eat and when you sleep matters: circadian dysfunction revealed as a direct hepatic carcinogen in a humanized mouse model.
    J Hepatol. 2023 Nov 17:S0168-8278(23)05277-7. doi: 10.1016/j.jhep.2023.
    >> Share

  452. CELSA C, Cabibbo G, Am Fulgenzi C, Scheiner B, et al
    Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
    J Hepatol. 2023 Nov 14:S0168-8278(23)05272-8. doi: 10.1016/j.jhep.2023.
    >> Share

  453. SHAO T, Chen YL
    Stop using the misidentified cell line - LO2 as a human hepatocyte.
    J Hepatol. 2023 Nov 9:S0168-8278(23)05268-6. doi: 10.1016/j.jhep.2023.
    >> Share

  454. LIU J, Qian J, Yang Z, Zhou L, et al
    Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05231-5. doi: 10.1016/j.jhep.2023.
    >> Share

  455. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
    Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
    >> Share

  456. TELLEZ L, Payance A, Tjwa E, Del Cerro MJ, et al
    EASL-ERN position paper on liver involvement in patients with Fontan-type circulation.
    J Hepatol. 2023;79:1270-1301.
    >> Share

  457. ROCA-FERNANDEZ A, Banerjee R, Thomaides-Brears H, Telford A, et al
    Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
    J Hepatol. 2023;79:1085-1095.
    >> Share

    October 2023
  458. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
    Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976].
    J Hepatol. 2023 Oct 31:S0168-8278(23)05179-6. doi: 10.1016/j.jhep.2023.
    >> Share

  459. BIBO W, Hao S, Yating W, Fucheng L, et al
    Balance of Gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration.
    J Hepatol. 2023 Oct 31:S0168-8278(23)05183-8. doi: 10.1016/j.jhep.2023.
    >> Share

  460. PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
    Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
    J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
    >> Share

  461. FERNANDEZ-GARZA LE
    5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?
    J Hepatol. 2023 Oct 25:S0168-8278(23)05228-5. doi: 10.1016/j.jhep.2023.
    >> Share

  462. MUCKE MM, Fong S, Foster GR, Lillicrap D, et al
    Adeno-associated viruses for gene therapy - clinical implications and liver related complications, a guide for hepatologists.
    J Hepatol. 2023 Oct 25:S0168-8278(23)05229-7. doi: 10.1016/j.jhep.2023.
    >> Share

  463. RATZIU V, Hompesch M, Petitjean M, Serdjebi C, et al
    Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions.
    J Hepatol. 2023 Oct 23:S0168-8278(23)05182-6. doi: 10.1016/j.jhep.2023.
    >> Share

  464. CAMPION D, Ponzo P, Risso A, Caropreso P, et al
    A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
    J Hepatol. 2023 Oct 19:S0168-8278(23)05176-0. doi: 10.1016/j.jhep.2023.
    >> Share

  465. MAIWALL R, Rao Pasupuleti SS, Sarin SK
    AUTHORS REPLY: High versus low target mean arterial pressure in septic shock in cirrhosis-A personalized TARGET-C approach may solve the conundrum!
    J Hepatol. 2023 Oct 13:S0168-8278(23)05144-9. doi: 10.1016/j.jhep.2023.
    >> Share

  466. ZHANG L, Xu J, Zhou S, Yao F, et al
    Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
    J Hepatol. 2023 Oct 12:S0168-8278(23)05170-X. doi: 10.1016/j.jhep.2023.
    >> Share

  467. CHEN X, Pan J, Zhu Y
    Anticoagulation for cirrhosis with portal vein thrombosis: Still a road to be explored.
    J Hepatol. 2023 Oct 11:S0168-8278(23)05163-2. doi: 10.1016/j.jhep.2023.
    >> Share

  468. KANG MG, Lee CH, Shen C, Kim JS, et al
    Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea.
    J Hepatol. 2023 Oct 10:S0168-8278(23)05166-8. doi: 10.1016/j.jhep.2023.
    >> Share

  469. SHA M, Cao J, Xia Q
    Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
    >> Share

  470. CHE-TO LAI J, Lai-Hung Wong G, Cheuk-Fung Yip T
    Reply to "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
    J Hepatol. 2023 Oct 9:S0168-8278(23)05165-6. doi: 10.1016/j.jhep.2023.
    >> Share

  471. GRONBAEK L, Gronbaek H
    Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
    J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
    >> Share

  472. TRUSSONI CE, LaRusso NF
    Macrophages make a difference in cholestatic liver diseases - but how?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05149-8. doi: 10.1016/j.jhep.2023.
    >> Share

  473. ABERG F, Savikko J, Eerola V, Nordin A, et al
    High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology.
    J Hepatol. 2023 Oct 7:S0168-8278(23)05145-0. doi: 10.1016/j.jhep.2023.
    >> Share

  474. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
    Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
    J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
    >> Share

  475. LU W
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
    J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
    >> Share

  476. GROBA SR, Soehnlein O
    DRANquilizing neutrophil function in chronic liver disease.
    J Hepatol. 2023;79:885-887.
    >> Share

  477. ROMERO-GOMEZ M, Lawitz E, Shankar RR, Chaudhri E, et al
    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2023;79:888-897.
    >> Share

  478. LI L, Wang Z, Jiang Y
    Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again.
    J Hepatol. 2023;79:e164-e165.
    >> Share

  479. GUO R, Xu X, Babcock SA, Zhang Y, et al
    Retraction notice to "Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy" [J Hepatol 62 (3) (2015) 647-656].
    J Hepatol. 2023;79:1072.
    >> Share

    September 2023

  480. Corrigendum to "EASL Clinical Practice Guidelines on haemochromatosis" [J Hepatol 2022 (77) 479-502].
    J Hepatol. 2023 Sep 26:S0168-8278(23)05088-2. doi: 10.1016/j.jhep.2023.
    >> Share


  481. Corrigendum to "EASL clinical practice guidelines on the management of hepatic encephalopathy" [J Hepatol 2022 (77) 807-824].
    J Hepatol. 2023 Sep 26:S0168-8278(23)05090-0. doi: 10.1016/j.jhep.2023.
    >> Share


  482. Corrigendum to "EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma" [J Hepatol (79) (2023) 181-208].
    J Hepatol. 2023 Sep 23:S0168-8278(23)05092-4. doi: 10.1016/j.jhep.2023.
    >> Share


  483. Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].
    J Hepatol. 2023 Sep 19:S0168-8278(23)05091-2. doi: 10.1016/j.jhep.2023.
    >> Share

  484. LALEMAN W, Vanderschueren E, Mehdi ZS, Wiest R, et al
    Endoscopic procedures in HEPATOLOGY:CURRENT trends and new developments.
    J Hepatol. 2023 Sep 18:S0168-8278(23)05101-2. doi: 10.1016/j.jhep.2023.
    >> Share


  485. Corrigendum to "EASL clinical practice guidelines on the management of cystic liver diseases" [J Hepatol (77) 1083-1108].
    J Hepatol. 2023 Sep 17:S0168-8278(23)05089-4. doi: 10.1016/j.jhep.2023.
    >> Share

  486. CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
    Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
    >> Share

  487. NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
    AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
    >> Share

  488. CHEN X, Chen S, Pang J, Huang R, et al
    Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux.
    J Hepatol. 2023 Sep 5:S0168-8278(23)05077-8. doi: 10.1016/j.jhep.2023.
    >> Share

  489. WANG Q, Bu Q, Zhou H, Lu L, et al
    Reply to?"Short-term activation of PERK alleviates the progression of experimental nonalcoholic steatohepatitis".
    J Hepatol. 2023 Sep 4:S0168-8278(23)05076-6. doi: 10.1016/j.jhep.2023.
    >> Share

    August 2023
  490. CHEN R, Huang B, Lian M, Wei Y, et al
    A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
    J Hepatol. 2023 Aug 31:S0168-8278(23)05069-9. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  491. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    >> Share

  492. ARINO S, Aguilar-Bravo B, Coll M, Lee WY, et al
    Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00423-3. doi: 10.1016/j.jhep.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016